<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CIALIS- tadalafilÂ tablet, film coatedÂ </strong><br>Aphena Pharma Solutions - Tennessee, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CIALIS safely and effectively. See full prescribing information for CIALIS. <br>
CIALIS (tadalafil) tablets, for oral use<br>
Initial U.S. Approval: 2003
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" width="82.150%">
<col align="left" width="17.850%">
<tbody class="Headless">
<tr>
<td align="left" valign="top"><p class="Highlighta">Indications and Usage, Limitation of Use (<a href="#s3c">1.4</a>)<br> </p></td>
<td align="left" valign="top"><p class="Highlighta">10/2013<br> </p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="Highlighta">Dosage and Administration, CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span> (<a href="#s7a">2.3</a>)<br> </p></td>
<td align="left" valign="top"><p class="Highlighta"><br>10/2013<br> </p></td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">CIALIS<span class="Sup">Â®</span> is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of:
 </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (ED) (<a href="#s3">1.1</a>)
</li>
<li>the signs and symptoms of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH) (<a href="#s3a">1.2</a>)
</li>
<li>ED and the signs and symptoms of BPH (ED/BPH) (<a href="#s3b">1.3</a>)
</li>
</ul>
<p class="Highlighta">If CIALIS is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks (<a href="#s3c">1.4</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">CIALIS for use as needed:</span><ul class="Disc"><li>ED: Starting dose: 10Â mg as needed prior to sexual activity. Increase to 20Â mg or decrease to 5Â mg based upon efficacy/tolerability. Improves erectile function compared to placebo up to 36 hours post dose. Not to be taken more than once per day (<a href="#s5">2.1</a>).
</li></ul>
</li>
<li>
<span class="Italics">CIALIS for once daily use:</span><ul class="Disc">
<li>ED: 2.5Â mg taken once daily, without regard to timing of sexual activity. May increase to 5 mg based upon efficacy and tolerability (<a href="#s7">2.2</a>).
</li>
<li>BPH: 5Â mg, taken at approximately the same time every day (<a href="#s7a">2.3</a>)
</li>
<li>ED and BPH: 5Â mg, taken at approximately the same time every day (<a href="#s7a">2.3</a>, <a href="#s7b">2.4</a>)
</li>
</ul>
</li>
<li>CIALIS may be taken without regard to food (<a href="#s8">2.5</a>).
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 2.5Â mg, 5Â mg, 10Â mg, 20Â mg (<a href="#s23">3</a>).
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Administration of CIALIS to patients using any form of organic nitrate is contraindicated. CIALIS was shown to potentiate the hypotensive effect of nitrates (<a href="#s25">4.1</a>).
</li>
<li>History of known serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to CIALIS or ADCIRCA<span class="Sup">Â®</span> (<a href="#s25a">4.2</a>).
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Patients should not use CIALIS if sex is inadvisable due to cardiovascular status (<a href="#s27">5.1</a>).
</li>
<li>Use of CIALIS with alpha-blockers, antihypertensives or substantial amounts of alcohol (â‰¥5 units) may lead to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<a href="#s32">5.6</a>, <a href="#s39">5.9</a>).
</li>
<li>CIALIS is not recommended in combination with alpha-blockers for the treatment of BPH because efficacy of the combination has not been adequately studied and because of the risk of blood pressure lowering. Caution is advised when CIALIS is used as a treatment for ED in men taking alpha-blockers. (<a href="#s17">2.7</a>, <a href="#s32">5.6</a>, <a href="#s50">7.1</a>, <a href="#s83">12.2</a>)
</li>
<li>Patients should seek emergency treatment if an erection lasts &gt;4 hours. Use CIALIS with caution in patients predisposed to <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (<a href="#s29">5.3</a>).
</li>
<li>Patients should stop CIALIS and seek medical care if a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> occurs in one or both eyes, which could be a sign of Non <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">Arteritic Ischemic Optic Neuropathy</span> (NAION). Discuss increased risk of NAION in patients with history of NAION (<a href="#s30">5.4</a>).
</li>
<li>Patients should stop CIALIS and seek prompt medical attention in the event of sudden decrease or loss of hearing (<a href="#s31">5.5</a>).
</li>
<li>Prior to initiating treatment with CIALIS for BPH, consideration should be given to other urological conditions that may cause similar symptoms (<a href="#s43a">5.14</a>).
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥2%) include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in limb</span> (<a href="#s45">6.1</a>).
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div><div></div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>CIALIS can potentiate the hypotensive effects of nitrates, alpha-blockers, antihypertensives or alcohol (<a href="#s50">7.1</a>).
</li>
<li>CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure (<a href="#s17">2.7</a>, <a href="#s40">5.10</a>, <a href="#s55">7.2</a>) requiring dose adjustment:
                           <ul class="Disc">
<li>CIALIS for use as needed: no more than 10 mg every 72 hours</li>
<li>CIALIS for once daily use: dose not to exceed 2.5 mg</li>
</ul>
</li>
<li>CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure (<a href="#s55">7.2</a>).
</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (<a href="#s9">2.6</a>, <a href="#s36">5.8</a>, <a href="#s77">8.6</a>):
 </p>
<ul class="Disc">
<li>Mild or Moderate: Dosage adjustment may be needed.
</li>
<li>Severe: Use is not recommended.
</li>
</ul>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#s9">2.6</a>, <a href="#s33">5.7</a>, <a href="#s78">8.7</a>):
 </p>
<ul class="Disc">
<li>Patients with creatinine clearance 30 to 50Â mL/min: Dosage adjustment may be needed.
</li>
<li>Patients with creatinine clearance less than 30Â mL/min or on hemodialysis: For use as needed: Dose should not exceed 5Â mg every 72 hours. Once daily use is not recommended.
</li>
</ul>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 3/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span> and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Limitation of Use
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 CIALIS for Use as Needed for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span> and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Use with Food</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Use in Specific Populations</a></h2>
<h2><a href="#section-2.8" class="toc">2.7 Concomitant Medications</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Nitrates</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Cardiovascular</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Potential for Drug Interactions When Taking CIALIS for Once Daily Use</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Prolonged Erection</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Eye</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="374053" conceptname="Sudden hearing loss">Sudden Hearing Loss</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Alpha-blockers and Antihypertensives</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Alcohol</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4)</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Combination With Other PDE5 Inhibitors or <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span> Therapies</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Effects on <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Counseling Patients About <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic Interactions</span> with CIALIS</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for Other Drugs to Affect CIALIS</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Potential for CIALIS to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 CIALIS for Use as Needed for ED</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 CIALIS for Once Daily Use for ED</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 CIALIS 5Â mg for Once Daily Use for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span> (BPH)
</a></h2>
<h2><a href="#section-13.4" class="toc">14.4 CIALIS 5Â mg for Once Daily Use for ED and BPH
</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.2" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.3" class="toc">16.2 Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Nitrates</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Cardiovascular Considerations</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Concomitant Use with Drugs Which Lower Blood Pressure</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Potential for Drug Interactions When Taking CIALIS for Once Daily Use</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Vision</a></h2>
<h2><a href="#section-15.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="374053" conceptname="Sudden hearing loss">Sudden Hearing Loss</span></a></h2>
<h2><a href="#section-15.8" class="toc">17.8 Alcohol</a></h2>
<h2><a href="#section-15.9" class="toc">17.9 <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Disease</span></a></h2>
<h2><a href="#section-15.10" class="toc">17.10 Recommended Administration
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></h2>
<p class="First">CIALIS<span class="Sup">Â®</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (ED).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3a"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</h2>
<p class="First">
									CIALIS is indicated for the treatment of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3b"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span> and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</h2>
<p class="First">
									CIALIS is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3c"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Limitation of Use
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>If CIALIS is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of CIALIS decreases from 4 weeks until 26 weeks, and the incremental benefit of CIALIS beyond 26 weeks is unknown <span class="Italics">[see Clinical Studies (<a href="#s122a">14.3</a>)]</span>. 
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Do not split CIALIS tablets; entire dose should be taken.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 CIALIS for Use as Needed for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></h2>
<ul class="Disc">
<li>The recommended starting dose of CIALIS for use as needed in most patients is 10Â mg, taken prior to anticipated sexual activity.</li>
<li>The dose may be increased to 20Â mg or decreased to 5Â mg, based on individual efficacy and tolerability. The maximum recommended dosing frequency is once per day in most patients.</li>
<li>CIALIS for use as needed was shown to improve erectile function compared to placebo up to 36 hours following dosing. Therefore, when advising patients on optimal use of CIALIS, this should be taken into consideration.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></h2>
<ul class="Disc">
<li>The recommended starting dose of CIALIS for once daily use is 2.5 mg, taken at approximately the same time every day, without regard to timing of sexual activity. </li>
<li>
												The CIALIS dose for once daily use may be increased to 5Â mg, based on individual efficacy and tolerability.
											</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7a"></a><a name="section-2.3"></a><p></p>
<h2>2.3 CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</h2>
<ul class="Disc">
<li>The recommended dose of CIALIS for once daily use is 5Â mg, taken at approximately the same time every day.</li>
<li style="border-left:1px solid;">
<span class="XmChange"></span>When therapy for BPH is initiated with CIALIS and finasteride, the recommended dose of CIALIS for once daily use is 5 mg, taken at approximately the same time every day for up to 26 weeks.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7b"></a><a name="section-2.4"></a><p></p>
<h2>2.4 CIALIS for Once Daily Use for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span> and <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span>
</h2>
<p class="First">The recommended dose of CIALIS for once daily use is 5Â mg, taken at approximately the same time every day, without regard to timing of sexual activity.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Use with Food</h2>
<p class="First">CIALIS may be taken without regard to food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Use in Specific Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.6.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.6.1.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Use as Needed</span></p>
<ul class="Disc">
<li>
														Creatinine clearance 30 to 50Â mL/min: A starting dose of 5Â mg not more than once per day is recommended, and the maximum dose is 10Â mg not more than once in every 48 hours.
</li>
<li>
														Creatinine clearance less than 30Â mL/min or on hemodialysis: The maximum dose is 5Â mg not more than once in every 72Â hours <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.7</a>) and Use in Specific Populations (<a href="#s78">8.7</a>)]</span>.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.6.1.2"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s12a"></a><a name="section-2.6.1.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span></span></p>
<ul class="Disc"><li>
																Creatinine clearance less than 30Â mL/min or on hemodialysis: CIALIS for once daily use is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.7</a>) and Use in Specific Populations (<a href="#s78">8.7</a>)]</span>.
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12b"></a><a name="section-2.6.1.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span>/<span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span></span></p>
<ul class="Disc">
<li>
																Creatinine clearance 30 to 50Â mL/min: A starting dose of 2.5Â mg is recommended. An increase to 5Â mg may be considered based on individual response.
</li>
<li>Creatinine clearance less than 30Â mL/min or on hemodialysis: CIALIS for once daily use is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#s33">5.7</a>) and Use in Specific Populations (<a href="#s78">8.7</a>)]</span>.
</li>
</ul>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-2.7"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-2.7.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Use as Needed</span></p>
<ul class="Disc">
<li>Mild or moderate (Child Pugh Class A or B): The dose should not exceed 10Â mg once per day. The use of CIALIS once per day has not been extensively evaluated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and therefore, caution is advised.
</li>
<li>Severe (Child Pugh Class C): The use of CIALIS is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#s36">5.8</a>) and Use in Specific Populations (<a href="#s77">8.6</a>)]</span>.
                                 </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-2.7.2"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use</span></p>
<ul class="Disc">
<li>Mild or moderate (Child Pugh Class A or B): CIALIS for once daily use has not been extensively evaluated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Therefore, caution is advised if CIALIS for once daily use is prescribed to these patients.
</li>
<li>Severe (Child Pugh Class C): The use of CIALIS is not recommended <span class="Italics">[see Warnings and Precautions (<a href="#s36">5.8</a>) and Use in Specific Populations (<a href="#s77">8.6</a>)]</span>.
                                 </li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-2.8"></a><p></p>
<h2>2.7 Concomitant Medications</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-2.8.1"></a><p></p>
<p class="First"><span class="Underline">Nitrates</span></p>
<p> Concomitant use of nitrates in any form is contraindicated <span class="Italics">[see Contraindications (<a href="#s25">4.1</a>)]</span>.
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-2.8.2"></a><p></p>
<p class="First"><span class="Underline">Alpha-Blockers</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s19a"></a><a name="section-2.8.2.1"></a><p></p>
<p class="First"><span class="Italics">ED</span> â€” When CIALIS is coadministered with an alpha-blocker in patients being treated for ED, patients should be stable on alpha-blocker therapy prior to initiating treatment, and CIALIS should be initiated at the lowest recommended dose <span class="Italics">[see Warnings and Precautions (<a href="#s32">5.6</a>), Drug Interactions (<a href="#s50">7.1</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19b"></a><a name="section-2.8.2.2"></a><p></p>
<p class="First"><span class="Italics">BPH</span> â€” CIALIS is not recommended for use in combination with alpha-blockers for the treatment of BPH <span class="Italics">[see Warnings and Precautions (<a href="#s32">5.6</a>), Drug Interactions (<a href="#s50">7.1</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-2.8.3"></a><p></p>
<p class="First"><span class="Underline">CYP3A4 Inhibitors</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-2.8.3.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Use as Needed</span> â€” For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of CIALIS is 10Â mg, not to exceed once every 72 hours <span class="Italics">[see Warnings and Precautions (<a href="#s40">5.10</a>) and Drug Interactions (<a href="#s55">7.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-2.8.3.2"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use</span> â€” For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose is 2.5Â mg <span class="Italics">[see Warnings and Precautions (<a href="#s40">5.10</a>) and Drug Interactions (<a href="#s55">7.2</a>)]</span>.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s23"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Four strengths of almond-shaped tablets are available in different sizes and different shades of yellow:
</p>
<dl>
<dt>Â </dt>
<dd>2.5 mg tablets debossed with â€œC 2Â 1/2â€?</dd>
<dt>Â </dt>
<dd>5 mg tablets debossed with â€œCÂ 5â€?</dd>
<dt>Â </dt>
<dd>10 mg tablets debossed with â€œCÂ 10â€?</dd>
<dt>Â </dt>
<dd>20 mg tablets debossed with â€œCÂ 20â€?</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s24"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Nitrates</h2>
<p class="First">Administration of CIALIS to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated. In clinical pharmacology studies, CIALIS was shown to potentiate the hypotensive effect of nitrates <span class="Italics">[see Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25a"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">CIALIS is contraindicated in patients with a known serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tadalafil (CIALIS or ADCIRCA<span class="Sup">Â®</span>). <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> <span class="Italics">[see Adverse Reactions (<a href="#s48">6.2</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s26"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">Evaluation of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> and BPH should include an appropriate medical assessment to identify potential underlying causes, as well as treatment options.</p>
<p>Before prescribing CIALIS, it is important to note the following:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Cardiovascular</h2>
<p class="First">Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Therefore, treatments for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, including CIALIS, should not be used in men for whom sexual activity is inadvisable as a result of their underlying cardiovascular status. Patients who experience symptoms upon initiation of sexual activity should be advised to refrain from further sexual activity and seek immediate medical attention.</p>
<p>Physicians should discuss with patients the appropriate action in the event that they experience anginal <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> requiring nitroglycerin following intake of CIALIS. In such a patient, who has taken CIALIS, where nitrate administration is deemed medically necessary for a life-threatening situation, at least 48Â hours should have elapsed after the last dose of CIALIS before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring. Therefore, patients who experience anginal <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> after taking CIALIS should seek immediate medical attention. <span class="Italics">[see Contraindications (<a href="#s25">4.1</a>) and Patient Counseling Information (<a href="#s127">17.1</a>)]</span>.</p>
<p>Patients with left ventricular outflow obstruction, (e.g., <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span> and <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">idiopathic hypertrophic subaortic stenosis</span>) can be sensitive to the action of vasodilators, including PDE5 inhibitors.</p>
<p>The following groups of patients with cardiovascular disease were not included in clinical safety and efficacy trials for CIALIS, and therefore until further information is available, CIALIS is not recommended for the following groups of patients:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> within the last 90 days
</li>
<li><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or angina occurring during sexual intercourse
</li>
<li>New York Heart Association Class 2 or greater <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in the last 6 months
</li>
<li>uncontrolled <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (&lt;90/50Â mmÂ Hg), or <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> within the last 6 months.
</li>
</ul>
<p>As with other PDE5 inhibitors, tadalafil has mild systemic vasodilatory properties that may result in transient decreases in blood pressure. In a clinical pharmacology study, tadalafil 20Â mg resulted in a mean maximal decrease in supine blood pressure, relative to placebo, of 1.6/0.8Â mmÂ Hg in healthy subjects <span class="Italics">[see Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>. While this effect should not be of consequence in most patients, prior to prescribing CIALIS, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects. Patients with severely impaired autonomic control of blood pressure may be particularly sensitive to the actions of vasodilators, including PDE5 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Potential for Drug Interactions When Taking CIALIS for Once Daily Use</h2>
<p class="First">Physicians should be aware that CIALIS for once daily use provides continuous plasma tadalafil levels and should consider this when evaluating the potential for interactions with medications (e.g., nitrates, alpha-blockers, anti-hypertensives and potent inhibitors of CYP3A4) and with substantial consumption of alcohol <span class="Italics">[see Drug Interactions (<a href="#s50">7.1</a>, <a href="#s55">7.2</a>, <a href="#s63">7.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Prolonged Erection</h2>
<p class="First">There have been rare reports of prolonged erections greater than 4 hours and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (<span class="product-label-link" type="condition" conceptid="4213599" conceptname="Painful penile erection">painful erections</span> greater than 6 hours in duration) for this class of compounds. <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span>, if not treated promptly, can result in irreversible damage to the erectile tissue. Patients who have an erection lasting greater than 4 hours, whether painful or not, should seek emergency medical attention.</p>
<p>CIALIS should be used with caution in patients who have conditions that might predispose them to <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (such as <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>), or in patients with anatomical deformation of the penis (such as angulation, cavernosal <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, or Peyronie's disease).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Eye</h2>
<p class="First">Physicians should advise patients to stop use of all PDE5 inhibitors, including CIALIS, and seek medical attention in the event of a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in one or both eyes. Such an event may be a sign of non-arteritic anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span> (NAION), a cause of decreased vision, including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or other factors. Physicians should also discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators such as PDE5 inhibitors <span class="Italics">[see Adverse Reactions (<a href="#s48">6.2</a>)]</span>.</p>
<p>Patients with known hereditary degenerative <span class="product-label-link" type="condition" conceptid="378416" conceptname="Retinal disorder">retinal disorders</span>, including <span class="product-label-link" type="condition" conceptid="4103381" conceptname="Retinitis pigmentosa">retinitis pigmentosa</span>, were not included in the clinical trials, and use in these patients is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="374053" conceptname="Sudden hearing loss">Sudden Hearing Loss</span></h2>
<p class="First">Physicians should advise patients to stop taking PDE5 inhibitors, including CIALIS, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, have been reported in temporal association to the intake of PDE5 inhibitors, including CIALIS. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors <span class="Italics">[see Adverse Reactions (<a href="#s45">6.1</a>, <a href="#s48">6.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Alpha-blockers and Antihypertensives</h2>
<p class="First">Physicians should discuss with patients the potential for CIALIS to augment the blood-pressure-lowering effect of alpha-blockers and antihypertensive medications <span class="Italics">[see Drug Interactions (<a href="#s50">7.1</a>) and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
<p>Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including CIALIS, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly <span class="Italics">[see Drug Interactions (<a href="#s50">7.1</a>) and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>, which may lead to symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (e.g., <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>). Consideration should be given to the following:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32a"></a><a name="section-5.6.1"></a><p></p>
<p class="First"><span class="Underline">ED</span></p>
<ul class="Disc">
<li>Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Patients who demonstrate <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span> on alpha-blocker therapy alone are at increased risk of symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with concomitant use of PDE5 inhibitors.
</li>
<li>In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended dose.
</li>
<li>In those patients already taking an optimized dose of PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor.
</li>
<li>Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> and other antihypertensive drugs.</li>
</ul>
<p><span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>) and Drug Interactions (<a href="#s50">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32b"></a><a name="section-5.6.2"></a><p></p>
<p class="First"><span class="Underline">BPH</span></p>
<ul class="Disc">
<li>The efficacy of the coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>), Drug Interactions (<a href="#s50">7.1</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>.)]</span>.
</li>
<li>Patients on alpha-blocker therapy for BPH should discontinue their alpha-blocker at least one day prior to starting CIALIS for once daily use for the treatment of BPH.
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-5.7.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Use as Needed</span></p>
<p>CIALIS should be limited to 5Â mg not more than once in every 72 hours in patients with creatinine clearance less than 30Â mL/min or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis. The starting dose of CIALIS in patients with creatinine clearance 30Â â€“Â 50Â mL/min should be 5Â mg not more than once per day, and the maximum dose should be limited to 10Â mg not more than once in every 48 hours. <span class="Italics">[see Use in Specific Populations (<a href="#s78">8.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-5.7.2"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s35a"></a><a name="section-5.7.2.1"></a><p></p>
<p class="First"><span class="Underline">ED</span></p>
<p>Due to increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis, CIALIS for once daily use is not recommended in patients with creatinine clearance less than 30Â mL/min <span class="Italics">[see Use in Specific Populations (<a href="#s78">8.7</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35b"></a><a name="section-5.7.2.2"></a><p></p>
<p class="First"><span class="Underline">BPH and ED/BPH</span></p>
<p>Due to increased tadalafil exposure (AUC), limited clinical experience, and the lack of ability to influence clearance by dialysis, CIALIS for once daily use is not recommended in patients with creatinine clearance less than 30Â mL/min. In patients with creatinine clearance 30 â€“ 50Â mL/min, start dosing at 2.5Â mg once daily, and increase the dose to 5Â mg once daily based upon individual response <span class="Italics">[see Dosage and Administration (<a href="#s9">2.6</a>), Use in Specific Populations (<a href="#s78">8.7</a>), and Clinical Pharmacology (<a href="#s101">12.3</a>)]</span>.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-5.8.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Use as Needed</span></p>
<p>In patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the dose of CIALIS should not exceed 10Â mg. Because of insufficient information in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, use of CIALIS in this group is not recommended <span class="Italics">[see Use in Specific Populations (<a href="#s77">8.6</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-5.8.2"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use</span></p>
<p>
CIALIS for once daily use has not been extensively evaluated in patients with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Therefore, caution is advised if CIALIS for once daily use is prescribed to these patients. Because of insufficient information in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, use of CIALIS in this group is not recommended <span class="Italics">[see Use in Specific Populations (<a href="#s77">8.6</a>)]</span>.
										</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Alcohol</h2>
<p class="First">Patients should be made aware that both alcohol and CIALIS, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Therefore, physicians should inform patients that substantial consumption of alcohol (e.g., 5Â units or greater) in combination with CIALIS can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="Italics">[see Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Concomitant Use of Potent Inhibitors of Cytochrome P450 3A4 (CYP3A4)</h2>
<p class="First">CIALIS is metabolized predominantly by CYP3A4 in the liver. The dose of CIALIS for use as needed should be limited to 10Â mg no more than once every 72 hours in patients taking potent inhibitors of CYP3A4 such as ritonavir, ketoconazole, and itraconazole <span class="Italics">[see Drug Interactions (<a href="#s55">7.2</a>)]</span>. In patients taking potent inhibitors of CYP3A4 and CIALIS for once daily use, the maximum recommended dose is 2.5Â mg <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Combination With Other PDE5 Inhibitors or <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile Dysfunction</span> Therapies</h2>
<p class="First">
                           The safety and efficacy of combinations of CIALIS and other PDE5 inhibitors or treatments for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> have not been studied. Inform patients not to take CIALIS with other PDE5 inhibitors, including ADCIRCA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Effects on <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Studies <span class="Italics">inÂ vitro</span> have demonstrated that tadalafil is a selective inhibitor of PDE5. PDE5 is found in platelets. When administered in combination with aspirin, tadalafil 20Â mg did not prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, relative to aspirin alone. CIALIS has not been administered to patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders or significant active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span>. Although CIALIS has not been shown to increase <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding times</span> in healthy subjects, use in patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders or significant active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> should be based upon a careful risk-benefit assessment and caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Counseling Patients About <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span></h2>
<p class="First">The use of CIALIS offers no protection against <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>. Counseling patients about the protective measures necessary to guard against <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>, including Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV) should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43a"></a><a name="section-5.14"></a><p></p>
<h2>5.14 Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH
</h2>
<p class="First">Prior to initiating treatment with CIALIS for BPH, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s44"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>Tadalafil was administered to over 9000 men during clinical trials worldwide. In trials of CIALIS for once daily use, a total of 1434, 905, and 115 were treated for at least 6 months, 1 year, and 2 years, respectively. For CIALIS for use as needed, over 1300 and 1000 subjects were treated for at least 6 months and 1 year, respectively.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Use as Needed for ED</span></p>
<p>In eight primary placebo-controlled clinical studies of 12 weeks duration, mean age was 59 years (range 22 to 88) and the discontinuation rate due to adverse events in patients treated with tadalafil 10 or 20Â mg was 3.1%, compared to 1.4% in placebo treated patients.
</p>
<p>When taken as recommended in the placebo-controlled clinical trials, the following adverse reactions were reported (<span class="Italics">see </span><a href="#t1">TableÂ 1</a>) for CIALIS for use as needed:
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Treatment-Emergent Adverse Reactions Reported by â‰¥2% of Patients Treated with CIALIS (10 or 20Â mg) and More Frequent on Drug than Placebo in the Eight Primary Placebo-Controlled Clinical Studies (Including a Study in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>) for CIALIS for Use as Needed for ED
</span></caption>
<col align="left" width="30.254%">
<col align="left" width="16.457%">
<col align="left" width="16.457%">
<col align="left" width="18.416%">
<col align="left" width="18.416%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> The term <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> includes: <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>(N=476)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 5 mg (N=151)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 10 mg (N=394)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 20 mg (N=635)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
<td class="Botrule Rrule" align="center" valign="top">11%
</td>
<td class="Botrule Rrule" align="center" valign="top">11%
</td>
<td class="Botrule Rrule" align="center" valign="top">15%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">8%
</td>
<td class="Botrule Rrule" align="center" valign="top">10%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
<td class="Botrule Rrule" align="center" valign="top">6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span><span class="Sup">a</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use for ED</span></p>
<p>In three placebo-controlled clinical trials of 12 or 24 weeks duration, mean age was 58 years (range 21 to 82) and the discontinuation rate due to adverse events in patients treated with tadalafil was 4.1%, compared to 2.8% in placebo-treated patients.
</p>
<p>The following adverse reactions were reported (<span class="Italics">see </span><a href="#t2">Table 2</a>) in clinical trials of 12 weeks duration:
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Treatment-Emergent Adverse Reactions Reported by â‰¥2% of Patients Treated with CIALIS for Once Daily Use (2.5Â or 5Â mg) and More Frequent on Drug than Placebo in the Three Primary Placebo-Controlled Phase 3 Studies of 12 weeks Treatment Duration (Including a Study in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>) for CIALIS for Once Daily Use for ED
</span></caption>
<col align="left" width="39.400%">
<col align="left" width="20.200%">
<col align="left" width="20.200%">
<col align="left" width="20.200%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>(N=248)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 2.5 mg<br>(N=196)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 5 mg<br>(N=304)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
</tr>
</tbody>
</table>
<p>The following adverse reactions were reported (<span class="Italics">see </span><a href="#t3">Table 3</a>) over 24 weeks treatment duration in one placebo-controlled clinical study:
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Treatment-Emergent Adverse Reactions Reported by â‰¥2% of Patients Treated with CIALIS for Once Daily Use (2.5Â or 5Â mg) and More Frequent on Drug than Placebo in One Placebo-Controlled Clinical Study of 24 Weeks Treatment Duration for CIALIS for Once Daily Use for ED
</span></caption>
<col align="left" width="51.750%">
<col align="left" width="12.900%">
<col align="left" width="18.525%">
<col align="left" width="16.825%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo<br>(N=94)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 2.5 mg<br>(N=96)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 5 mg<br>(N=97)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
<td class="Botrule Rrule" align="center" valign="top">6%
</td>
<td class="Botrule Rrule" align="center" valign="top">6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux disease</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">1%
</td>
<td class="Botrule Rrule" align="center" valign="top">3%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></span></td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">0%
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s47a"></a><a name="section-6.1.2.1"></a><p></p>
<p class="First"><span class="Italics">CIALIS for Once Daily Use for BPH and for ED and BPH</span></p>
<p>In three placebo-controlled clinical trials of 12 weeks duration, two in patients with BPH and one in patients with ED and BPH, the mean age was 63 years (range 44 to 93) and the discontinuation rate due to adverse events in patients treated with tadalafil was 3.6% compared to 1.6% in placebo-treated patients. Adverse reactions leading to discontinuation reported by at least 2 patients treated with tadalafil included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. The following adverse reactions were reported (<span class="Italics">see </span><a href="#t4">Table 4</a>).
</p>
<a name="t4"></a><table width="100%">
<caption><span>
Table 4: Treatment-Emergent Adverse Reactions Reported by â‰¥1% of Patients Treated with CIALIS for Once Daily Use (5Â mg) and More Frequent on Drug than Placebo in Three Placebo-Controlled Clinical Studies of 12 Weeks Treatment Duration, including Two Studies for CIALIS for Once Daily Use for BPH and One Study for ED and BPH
</span></caption>
<col align="left" width="39.487%">
<col align="left" width="30.257%">
<col align="left" width="30.257%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">
Adverse Reaction
</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">
Placebo<br>(N=576)
</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">
Tadalafil 5 mg<br>(N=581)
</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
2.3%
</td>
<td class="Botrule Rrule" align="center" valign="top">
4.1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
0.2%
</td>
<td class="Botrule Rrule" align="center" valign="top">
2.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
1.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">
2.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
1.6%
</td>
<td class="Botrule Rrule" align="center" valign="top">
2.1%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
1.0%
</td>
<td class="Botrule Rrule" align="center" valign="top">
1.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
0.0%
</td>
<td class="Botrule Rrule" align="center" valign="top">
1.4%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
0.3%
</td>
<td class="Botrule Rrule" align="center" valign="top">
1.2%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</span></td>
<td class="Botrule Rrule" align="center" valign="top">
0.5%
</td>
<td class="Botrule Rrule" align="center" valign="top">
1.0%
</td>
</tr>
</tbody>
</table>
<p>Additional, less frequent adverse reactions (&lt;1%) reported in the controlled clinical trials of CIALIS for BPH or ED and BPH included: <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> was reported at incidence rates described in Tables 1 through 4. In tadalafil clinical pharmacology trials, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours. The <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>/<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> associated with tadalafil treatment was characterized by diffuse bilateral lower lumbar, gluteal, thigh, or thoracolumbar muscular <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and was exacerbated by recumbency. In general, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was reported as mild or moderate in severity and resolved without medical treatment, but severe <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> was reported with a low frequency (&lt;5% of all reports). When medical treatment was necessary, acetaminophen or non-steroidal anti-inflammatory drugs were generally effective; however, in a small percentage of subjects who required treatment, a mild narcotic (e.g., codeine) was used. Overall, approximately 0.5% of all subjects treated with CIALIS for on demand use discontinued treatment as a consequence of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>/<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. In the 1-year open label extension study, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> were reported in 5.5% and 1.3% of patients, respectively. Diagnostic testing, including measures for <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle injury</span>, or renal damage revealed no evidence of medically significant underlying pathology. Incidence rates for CIALIS for once daily use for ED, BPH and BPH/ED are described in Tables 2, 3 and 4. In studies of CIALIS for once daily use, adverse reactions of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> were generally mild or moderate with a discontinuation rate of &lt;1% across all indications.
</p>
<p>Across all studies with any CIALIS dose, reports of changes in color vision were rare (&lt;0.1% of patients).
</p>
<p>The following section identifies additional, less frequent events (&lt;2%) reported in controlled clinical trials of CIALIS for once daily use or use as needed. A causal relationship of these events to CIALIS is uncertain. Excluded from this list are those events that were minor, those with no plausible relation to drug use, and reports too imprecise to be meaningful:
</p>
<p><span class="Bold Italics">Body as a Whole</span> â€” <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
</p>
<p><span class="Bold Italics">Cardiovascular</span> â€” <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>
</p>
<p><span class="Bold Italics">Digestive</span> â€” <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, GGTP increased, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span>, <span class="product-label-link" type="condition" conceptid="4198840" conceptname="Bleeding hemorrhoids">hemorrhoidal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>
</p>
<p><span class="Bold Italics">Musculoskeletal</span> â€” <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>
</p>
<p><span class="Bold Italics">Nervous</span> â€” <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>
</p>
<p><span class="Bold Italics">Renal and Urinary</span> â€” <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>
</p>
<p><span class="Bold Italics">Respiratory</span> â€” <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>
</p>
<p><span class="Bold Italics">Skin and Appendages</span> â€” <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
</p>
<p><span class="Bold Italics">Ophthalmologic</span> â€” <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, changes in color vision, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (including <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>), <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> increase, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">swelling of eyelids</span>
</p>
<p><span class="Bold Italics">Otologic</span> â€” sudden decrease or loss of hearing, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>
</p>
<p><span class="Bold Italics">Urogenital</span> â€” erection increased, spontaneous penile erection
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of CIALIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors.
</p>
<p><span class="Bold Italics">Cardiovascular and Cerebrovascular</span> â€” Serious cardiovascular events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, have been reported postmarketing in temporal association with the use of tadalafil. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of CIALIS without sexual activity. Others were reported to have occurred hours to days after the use of CIALIS and sexual activity. It is not possible to determine whether these events are related directly to CIALIS, to sexual activity, to the patient's underlying cardiovascular disease, to a combination of these factors, or to other factors <span class="Italics">[see Warnings and Precautions (<a href="#s27">5.1</a>)]</span>.</p>
<p><span class="Bold Italics">Body as a Whole</span> â€” <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>
</p>
<p><span class="Bold Italics">Nervous</span> â€” <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> recurrence, <span class="product-label-link" type="condition" conceptid="437306" conceptname="Transient global amnesia">transient global amnesia</span>
</p>
<p><span class="Bold Italics">Ophthalmologic</span> â€” <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="313761" conceptname="Central retinal vein occlusion">retinal vein occlusion</span>, <span class="product-label-link" type="condition" conceptid="4334245" conceptname="Retinal artery occlusion">retinal artery occlusion</span>
</p>
<p>Non-arteritic anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span> (NAION), a cause of decreased vision including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, has been reported rarely postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including CIALIS. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of NAION, including but not necessarily limited to: low cup to disc ratio (â€œcrowded discâ€?), age over 50, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, and smoking. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors, to the patient's underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors <span class="Italics">[see Warnings and Precautions (<a href="#s30">5.4</a>)]</span>.</p>
<p><span class="Bold Italics">Otologic</span> â€” Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including CIALIS. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of CIALIS, to the patient's underlying risk factors for <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, a combination of these factors, or to other factors <span class="Italics">[see Warnings and Precautions (<a href="#s31">5.5</a>)]</span>.</p>
<p><span class="Bold Italics">Urogenital</span> â€” <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> <span class="Italics">[see Warnings and Precautions (<a href="#s29">5.3</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s49"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacodynamic Interactions</span> with CIALIS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Underline">Nitrates</span> â€” Administration of CIALIS to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, CIALIS was shown to potentiate the hypotensive effect of nitrates. In a patient who has taken CIALIS, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of CIALIS before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>), Contraindications (<a href="#s25">4.1</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-7.1.2"></a><p></p>
<p class="First"><span class="Underline">Alpha-Blockers</span> â€” Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including CIALIS, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, tamsulosin or alfuzosin. <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>), Warnings and Precautions (<a href="#s32">5.6</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-7.1.3"></a><p></p>
<p class="First"><span class="Underline">Antihypertensives</span> â€” PDE5Â inhibitors, including tadalafil, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood-pressure-lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendrofluazide, enalapril, and metoprolol). Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo. <span class="Italics">[see Warnings and Precautions (<a href="#s32">5.6</a>) and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-7.1.4"></a><p></p>
<p class="First"><span class="Underline">Alcohol</span> â€” Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g.,Â 5Â units or greater) in combination with CIALIS can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. <span class="Italics">[see Warnings and Precautions (<a href="#s39">5.9</a>) and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for Other Drugs to Affect CIALIS</h2>
<p class="First"><span class="Italics">[See Dosage and Administration (<a href="#s17">2.7</a>) and Warnings and Precautions (<a href="#s40">5.10</a>)]</span>.
								</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Underline">Antacids</span> â€” Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering exposure (AUC) to tadalafil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Underline">H<span class="Sub">2 </span>Antagonists (e.g. Nizatidine)</span> â€” An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-7.2.3"></a><p></p>
<p class="First"><span class="Underline">Cytochrome P450 Inhibitors</span> â€” CIALIS is a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase tadalafil exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-7.2.4"></a><p></p>
<p class="First"><span class="Italics">CYP3A4 (e.g., Ketoconazole)</span> â€” Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased tadalafil 20Â mg single-dose exposure (AUC) by 312% and C<span class="Sub">max</span> by 22%, relative to the values for tadalafil 20Â mg alone. Ketoconazole (200Â mg daily) increased tadalafil 10-mg single-dose exposure (AUC) by 107% and C<span class="Sub">max</span> by 15%, relative to the values for tadalafil 10Â mg alone <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>)]</span>.</p>
<p>Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase tadalafil exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-7.2.5"></a><p></p>
<p class="First"><span class="Italics">HIV Protease inhibitor</span> â€” Ritonavir (500Â mg or 600Â mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in C<span class="Sub">max</span>, relative to the values for tadalafil 20Â mg alone. Ritonavir (200Â mg twice daily), increased tadalafil 20-mg single-dose exposure (AUC) by 124% with no change in C<span class="Sub">max</span>, relative to the values for tadalafil 20Â mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase tadalafil exposure <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-7.2.6"></a><p></p>
<p class="First"><span class="Underline">Cytochrome P450 Inducers</span> â€” Studies have shown that drugs that induce CYP3A4 can decrease tadalafil exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-7.2.7"></a><p></p>
<p class="First"><span class="Italics">CYP3A4 (e.g., Rifampin)</span> â€” Rifampin (600Â mg daily), a CYP3A4 inducer, reduced tadalafil 10-mg single-dose exposure (AUC) by 88% and C<span class="Sub">max</span> by 46%, relative to the values for tadalafil 10Â mg alone. Although specific interactions have not been studied, other CYP3A4 inducers, such as carbamazepine, phenytoin, and phenobarbital, would likely decrease tadalafil exposure. No dose adjustment is warranted. The reduced exposure of tadalafil with the coadministration of rifampin or other CYP3A4 inducers can be anticipated to decrease the efficacy of CIALIS for once daily use; the magnitude of decreased efficacy is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Potential for CIALIS to Affect Other Drugs</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-7.3.1"></a><p></p>
<p class="First"><span class="Underline">Aspirin</span> â€” Tadalafil did not potentiate the increase in <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> caused by aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-7.3.2"></a><p></p>
<p class="First"><span class="Underline">Cytochrome P450 Substrates</span> â€” CIALIS is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms. Studies have shown that tadalafil does not inhibit or induce P450 isoforms CYP1A2, CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-7.3.3"></a><p></p>
<p class="First"><span class="Italics">CYP1A2 (e.g. Theophylline)</span> â€” Tadalafil had no significant effect on the pharmacokinetics of theophylline. When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-7.3.4"></a><p></p>
<p class="First"><span class="Italics">CYP2C9 (e.g. Warfarin)</span> â€” Tadalafil had no significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time induced by warfarin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-7.3.5"></a><p></p>
<p class="First"><span class="Italics">CYP3A4 (e.g. Midazolam or Lovastatin)</span> â€” Tadalafil had no significant effect on exposure (AUC) to midazolam or lovastatin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-7.3.6"></a><p></p>
<p class="First"><span class="Underline">P-glycoprotein<span class="Italics Underline"> (e.g. Digoxin)</span></span> â€” Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant effect on the steady-state pharmacokinetics of digoxin (0.25 mg/day) in healthy subjects.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s70"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s71"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s72"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Category B</span> â€” CIALIS (tadalafil) is not indicated for use in women. There are no adequate and well controlled studies of CIALIS use in pregnant women.</p>
<p><span class="Underline">Risk Summary</span> â€” Based on animal data, CIALIS is not predicted to increase the risk of adverse developmental abnormalities in humans.</p>
<p><span class="Underline">Animal Data</span> â€” Animal reproduction studies showed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at exposures up to 11 times the maximum recommended human dose (MRHD) of 20Â mg/day during organogenesis. In one of two perinatal/postnatal developmental studies in rats, postnatal pup survival decreased following maternal exposure to tadalafil doses greater than 10 times the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 16 times the MRHD based on AUC. Surviving offspring had normal development and reproductive performance.
</p>
<p>In a rat prenatal and postnatal development study at doses of 60, 200, and 1000Â mg/kg, a reduction in postnatal survival of pups was observed. The no observed effect level (NOEL) for maternal toxicity was 200Â mg/kg/day and for developmental toxicity was 30Â mg/kg/day. This gives approximately 16 and 10 fold exposure multiples, respectively, of the human AUC for the MRHD of 20Â mg.
</p>
<p>Tadalafil and/or its metabolites cross the placenta, resulting in fetal exposure in rats.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s74"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">CIALIS is not indicated for use in women.</p>
<p>Tadalafil and/or its metabolites were secreted into the milk in lactating rats at concentrations approximately 2.4-fold greater than found in the plasma.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s75"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">CIALIS is not indicated for use in pediatric patients. Safety and efficacy in patients below the age of 18 years has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s76"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in ED clinical studies of tadalafil, approximately 25 percent were 65 and over, while approximately 3 percent were 75 and over. Of the total number of subjects in BPH clinical studies of tadalafil (including the ED/BPH study), approximately 40 percent were over 65, while approximately 10 percent were 75 and over. In these clinical trials, no overall differences in efficacy or safety were observed between older (&gt;65 and â‰¥75 years of age) and younger subjects (â‰¤65 years of age). Therefore no dose adjustment is warranted based on age alone. However, a greater sensitivity to medications in some older individuals should be considered. <span class="Italics">[see Clinical Pharmacology (<a href="#s101">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In clinical pharmacology studies, tadalafil exposure (AUC) in subjects with mild or moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh ClassÂ A or B) was comparable to exposure in healthy subjects when a dose of 10Â mg was administered. There are no available data for doses higher than 10Â mg of tadalafil in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Insufficient data are available for subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh ClassÂ C). <span class="Italics">[see Dosage and Administration (<a href="#s9">2.6</a>) and Warnings and Precautions (<a href="#s36">5.8</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In clinical pharmacology studies using single-dose tadalafil (5 to 10Â mg), tadalafil exposure (AUC) doubled in subjects with creatinine clearance 30 to 80Â mL/min. In subjects with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis, there was a two-fold increase in C<span class="Sub">max</span> and 2.7- to 4.8-fold increase in AUC following single-dose administration of 10 or 20Â mg tadalafil. Exposure to total methylcatechol (unconjugated plus glucuronide) was 2- to 4-fold higher in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, compared to those with normal renal function. Hemodialysis (performed between 24 and 30Â hours post-dose) contributed negligibly to tadalafil or metabolite elimination. In a clinical pharmacology study (N=28) at a dose of 10Â mg, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> was reported as a limiting adverse event in male patients with creatinine clearance 30 to 50 mL/min. At a dose of 5Â mg, the incidence and severity of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> was not significantly different than in the general population. In patients on hemodialysis taking 10- or 20-mg tadalafil, there were no reported cases of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. <span class="Italics">[see Dosage and Administration (<a href="#s9">2.6</a>) and Warnings and Precautions (<a href="#s33">5.7</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s79"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Single doses up to 500Â mg have been given to healthy subjects, and multiple daily doses up to 100Â mg have been given to patients. Adverse events were similar to those seen at lower doses. In cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, standard supportive measures should be adopted as required. Hemodialysis contributes negligibly to tadalafil elimination.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s80"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">CIALIS (tadalafil) is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Tadalafil has the empirical formula C<span class="Sub">22</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">4</span> representing a molecular weight of 389.41. The structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f001-structure-v1.jpg">
</div>
<p>The chemical designation is pyrazino[1Â´,2Â´:1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-. It is a crystalline solid that is practically insoluble in water and very slightly soluble in ethanol.
</p>
<p>CIALIS is available as almond-shaped tablets for oral administration. Each tablet contains 2.5, 5, 10, or 20Â mg of tadalafil and the following inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s81"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s82"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) enhances erectile function by increasing the amount of cGMP. Tadalafil inhibits PDE5. Because sexual stimulation is required to initiate the local release of nitric oxide, the inhibition of PDE5 by tadalafil has no effect in the absence of sexual stimulation.</p>
<p>The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum and pulmonary arteries is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The mechanism for reducing BPH symptoms has not been established.
</p>
<p>Studies <span class="Italics">inÂ vitro</span> have demonstrated that tadalafil is a selective inhibitor of PDE5. PDE5 is found in the smooth muscle of the corpus cavernosum, prostate, and bladder as well as in vascular and visceral smooth muscle, skeletal muscle, urethra, platelets, kidney, lung, cerebellum, heart, liver, testis, seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span>, and pancreas.
</p>
<p><span class="Italics">InÂ vitro</span> studies have shown that the effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. These studies have shown that tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4, and PDE7 enzymes, which are found in the heart, brain, blood vessels, liver, leukocytes, skeletal muscle, and other organs. Tadalafil is &gt;10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. Additionally, tadalafil is 700-fold more potent for PDE5 than for PDE6, which is found in the retina and is responsible for phototransduction. Tadalafil is &gt;9,000-fold more potent for PDE5 than for PDE8, PDE9, and PDE10. Tadalafil is 14-fold more potent for PDE5 than for PDE11A1 and 40-fold more potent for PDE5 than for PDE11A4, two of the four known forms of PDE11. PDE11 is an enzyme found in human prostate, testes, skeletal muscle and in other tissues (e.g., adrenal cortex). <span class="Italics">InÂ vitro</span>, tadalafil inhibits human recombinant PDE11A1 and, to a lesser degree, PDE11A4 activities at concentrations within the therapeutic range. The physiological role and clinical consequence of PDE11 inhibition in humans have not been defined.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s83"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s84"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Effects on Blood Pressure</span></p>
<p>Tadalafil 20Â mg administered to healthy male subjects produced no significant difference compared to placebo in supine systolic and diastolic blood pressure (difference in the mean maximal decrease of 1.6/0.8Â mmÂ Hg, respectively) and in standing systolic and diastolic blood pressure (difference in the mean maximal decrease of 0.2/4.6Â mmÂ Hg, respectively). In addition, there was no significant effect on heart rate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline">Effects on Blood Pressure When Administered with Nitrates</span></p>
<p>In clinical pharmacology studies, tadalafil (5 to 20Â mg) was shown to potentiate the hypotensive effect of nitrates. Therefore, the use of CIALIS in patients taking any form of nitrates is contraindicated <span class="Italics">[see Contraindications (<a href="#s25">4.1</a>)]</span>.</p>
<p>A study was conducted to assess the degree of interaction between nitroglycerin and tadalafil, should nitroglycerin be required in an emergency situation after tadalafil was taken. This was a double-blind, placebo-controlled, crossover study in 150 male subjects at least 40 years of age (including subjects with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and/or controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>) and receiving daily doses of tadalafil 20Â mg or matching placebo for 7 days. Subjects were administered a single dose of 0.4Â mg sublingual nitroglycerin (NTG) at pre-specified timepoints, following their last dose of tadalafil (2, 4, 8, 24, 48, 72, and 96 hours after tadalafil). The objective of the study was to determine when, after tadalafil dosing, no apparent blood pressure interaction was observed. In this study, a significant interaction between tadalafil and NTG was observed at each timepoint up to and including 24 hours. At 48 hours, by most hemodynamic measures, the interaction between tadalafil and NTG was not observed, although a few more tadalafil subjects compared to placebo experienced greater blood-pressure lowering at this timepoint. After 48 hours, the interaction was not detectable (<span class="Italics">see </span><a href="#f02">Figure 1</a>).</p>
<div class="Figure">
<a name="f02"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f002-v1.jpg"><p class="MultiMediaCaption">Figure 1: Mean Maximal Change in Blood Pressure (Tadalafil Minus Placebo, Point Estimate with 90%Â CI) in Response to Sublingual Nitroglycerin at 2 (Supine Only), 4, 8, 24, 48, 72, and 96Â Hours after the Last Dose of Tadalafil 20 mg or Placebo</p>
</div>
<p>Therefore, CIALIS administration with nitrates is contraindicated. In a patient who has taken CIALIS, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48Â hours should elapse after the last dose of CIALIS before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring <span class="Italics">[see Contraindications (<a href="#s25">4.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline">Effect on Blood Pressure When Administered With Alpha-Blockers</span></p>
<p>Six randomized, double-blinded, crossover clinical pharmacology studies were conducted to investigate the potential interaction of tadalafil with alpha-blocker agents in healthy male subjects <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>) and Warnings and Precautions (<a href="#s32">5.6</a>)]</span>. In four studies, a single oral dose of tadalafil was administered to healthy male subjects taking daily (at least 7Â days duration) an oral alpha-blocker. In two studies, a daily oral alpha-blocker (at least 7 days duration) was administered to healthy male subjects taking repeated daily doses of tadalafil.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s87"></a><a name="section-11.2.3.1"></a><p></p>
<p class="First"><span class="Italics">Doxazosin</span> â€” Three clinical pharmacology studies were conducted with tadalafil and doxazosin, an alpha[1]-adrenergic blocker.
</p>
<p>In the first doxazosin study, a single oral dose of tadalafil 20Â mg or placebo was administered in a 2-period, crossover design to healthy subjects taking oral doxazosin 8Â mg daily (N=18 subjects). Doxazosin was administered at the same time as tadalafil or placebo after a minimum of sevenÂ days of doxazosin dosing (<span class="Italics">see </span><a href="#t5">Table 5</a> and <a href="#f03">Figure 2</a>).</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Doxazosin (8Â mg/day) Study 1: Mean Maximal Decrease (95% CI) in Systolic Blood Pressure
</span></caption>
<col align="left" width="49.500%">
<col align="left" width="50.500%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo-subtracted mean maximal decrease in systolic blood pressure (mm Hg)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Tadalafil 20 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">3.6 (-1.5, 8.8)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">9.8 (4.1, 15.5)
</td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="f03"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f003-v1.jpg"><p class="MultiMediaCaption">Figure 2: Doxazosin Study 1: Mean Change from Baseline in Systolic Blood Pressure</p>
</div>
<p>Blood pressure was measured manually at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours after tadalafil or placebo administration. Outliers were defined as subjects with a standing systolic blood pressure of &lt;85Â mmÂ Hg or a decrease from baseline in standing systolic blood pressure of &gt;30Â mmÂ Hg at one or more time points. There were nine and threeÂ outliers following administration of tadalafil 20Â mg and placebo, respectively. Five and two subjects were outliers due to a decrease from baseline in standing systolic BP of &gt;30Â mmÂ Hg, while five and one subject were outliers due to standing systolic BP &lt;85Â mmÂ Hg following tadalafil and placebo, respectively. Severe adverse events potentially related to blood-pressure effects were assessed. No such events were reported following placebo. Two such events were reported following administration of tadalafil. <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span> was reported in one subject that began 7 hours after dosing and lasted about 5 days. This subject previously experienced a mild episode of <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> on doxazosin and placebo. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> was reported in another subject that began 25 minutes after dosing and lasted 1Â day. No <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported.</p>
<p>In the second doxazosin study, a single oral dose of tadalafil 20Â mg was administered to healthy subjects taking oral doxazosin, either 4 or 8Â mg daily. The study (N=72 subjects) was conducted in three parts, each a 3-period crossover.</p>
<p>In part A (N=24), subjects were titrated to doxazosin 4Â mg administered daily at 8Â a.m. Tadalafil was administered at either 8Â a.m., 4Â p.m., or 8Â p.m. There was no placebo control.</p>
<p>In part B (N=24), subjects were titrated to doxazosin 4Â mg administered daily at 8Â p.m. Tadalafil was administered at either 8Â a.m., 4Â p.m., or 8Â p.m. There was no placebo control.</p>
<p>In part C (N=24), subjects were titrated to doxazosin 8Â mg administered daily at 8Â a.m. In this part, tadalafil or placebo were administered at either 8Â a.m. or 8Â p.m.</p>
<p>The placebo-subtracted mean maximal decreases in systolic blood pressure over a 12-hour period after dosing in the placebo-controlled portion of the study (part C) are shown in <a href="#t6">Table 6</a> and <a href="#f04">Figure 3</a>.</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Doxazosin (8Â mg/day) Study 2 (Part C): Mean Maximal Decrease in Systolic Blood Pressure
</span></caption>
<col align="left" width="45.600%">
<col align="left" width="27.200%">
<col align="left" width="27.200%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo-subtracted mean maximal decrease in systolic blood pressure (mm Hg)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Tadalafil 20 mg at 8 a.m.</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Tadalafil 20 mg at 8 p.m.</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="right" valign="top">Ambulatory Blood-Pressure Monitoring (ABPM)
</td>
<td class="Botrule Rrule" align="center" valign="top">7
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="f04"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f004-v1.jpg"><p class="MultiMediaCaption">Figure 3: Doxazosin Study 2 (Part C): Mean Change from Time-Matched Baseline in Systolic Blood Pressure</p>
</div>
<p>Blood pressure was measured by ABPM every 15 to 30 minutes for up to 36 hours after tadalafil or placebo. Subjects were categorized as outliers if one or more systolic blood pressure readings of &lt;85Â mmÂ Hg were recorded or one or more decreases in systolic blood pressure of &gt;30Â mmÂ Hg from a time-matched baseline occurred during the analysis interval.</p>
<p>Of the 24 subjects in part C, 16 subjects were categorized as outliers following administration of tadalafil and 6 subjects were categorized as outliers following placebo during the 24-hour period after 8Â a.m. dosing of tadalafil or placebo. Of these, 5 and 2 were outliers due to systolic BP &lt;85Â mmÂ Hg, while 15 and 4 were outliers due to a decrease from baseline in systolic BP of &gt;30Â mmÂ Hg following tadalafil and placebo, respectively.</p>
<p>During the 24-hour period after 8Â p.m. dosing, 17 subjects were categorized as outliers following administration of tadalafil and 7 subjects following placebo. Of these, 10 and 2 subjects were outliers due to systolic BP &lt;85Â mmÂ Hg, while 15 and 5 subjects were outliers due to a decrease from baseline in systolic BP of &gt;30Â mmÂ Hg, following tadalafil and placebo, respectively.</p>
<p>Some additional subjects in both the tadalafil and placebo groups were categorized as outliers in the period beyond 24 hours.</p>
<p>Severe adverse events potentially related to blood-pressure effects were assessed. In the study (N=72Â subjects), 2 such events were reported following administration of tadalafil (symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in one subject that began 10 hours after dosing and lasted approximately 1 hour, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> in another subject that began 11 hours after dosing and lasted 2 minutes). No such events were reported following placebo. In the period prior to tadalafil dosing, one severe event (<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>) was reported in a subject during the doxazosin run-in phase.</p>
<p>In the third doxazosin study, healthy subjects (N=45 treated; 37 completed) received 28 days of once per day dosing of tadalafil 5Â mg or placebo in a two-period crossover design. After 7 days, doxazosin was initiated at 1Â mg and titrated up to 4Â mg daily over the last 21 days of each period (7 days on 1Â mg; 7 days of 2Â mg; 7 days of 4Â mg doxazosin). The results are shown in <a href="#t7">Table 7</a>.</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7: Doxazosin Study 3: Mean Maximal Decrease (95% CI) in Systolic Blood Pressure
</span></caption>
<col align="left" width="40.467%">
<col align="left" width="29.767%">
<col align="left" width="29.767%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Placebo-subtracted mean maximal decrease in systolic blood pressure</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 5 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">Day 1 of 4 mg Doxazosin</span></td>
<td class="Botrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">2.4 (-0.4, 5.2)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.5 (-4.0, 3.1)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">Day 7 of 4 mg Doxazosin</span></td>
<td class="Botrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">2.8 (-0.1, 5.7)
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">1.1 (-2.9, 5.0)
</td>
</tr>
</tbody>
</table>
<p>Blood pressure was measured manually pre-dose at two time points (-30 and -15 minutes) and then at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 hours post dose on the first day of each doxazosin dose, (1Â mg, 2Â mg, 4Â mg), as well as on the seventh day of 4Â mg doxazosin administration.
</p>
<p>Following the first dose of doxazosin 1Â mg, there were no outliers on tadalafil 5Â mg and one outlier on placebo due to a decrease from baseline in standing systolic BP of &gt;30Â mmÂ Hg.</p>
<p>There were 2 outliers on tadalafil 5Â mg and none on placebo following the first dose of doxazosin 2Â mg due to a decrease from baseline in standing systolic BP of &gt;30Â mmÂ Hg.</p>
<p>There were no outliers on tadalafil 5Â mg and two on placebo following the first dose of doxazosin 4Â mg due to a decrease from baseline in standing systolic BP of &gt;30Â mmÂ Hg. There was one outlier on tadalafil 5Â mg and three on placebo following the first dose of doxazosin 4Â mg due to standing systolic BP &lt;85Â mmÂ Hg. Following the seventh day of doxazosin 4Â mg, there were no outliers on tadalafil 5Â mg, one subject on placebo had a decrease &gt;30Â mmÂ Hg in standing systolic blood pressure, and one subject on placebo had standing systolic blood pressure &lt;85Â mmÂ Hg. All adverse events potentially related to blood pressure effects were rated as mild or moderate. There were two episodes of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> in this study, one subject following a dose of tadalafil 5Â mg alone, and another subject following coadministration of tadalafil 5Â mg and doxazosin 4Â mg.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-11.2.3.2"></a><p></p>
<p class="First"><span class="Italics">Tamsulosin</span> â€” In the first tamsulosin study, a single oral dose of tadalafil 10, 20Â mg, or placebo was administered in a 3 period, crossover design to healthy subjects taking 0.4Â mg once per day tamsulosin, a selective alpha[1A]-adrenergic blocker (N=18 subjects). Tadalafil or placebo was administered 2 hours after tamsulosin following a minimum of seven days of tamsulosin dosing.
</p>
<a name="t8"></a><table width="100%">
<caption><span>Table 8: Tamsulosin (0.4Â mg/day) Study 1: Mean Maximal Decrease (95% CI) in Systolic Blood Pressure
</span></caption>
<col align="left" width="40.867%">
<col align="left" width="29.733%">
<col align="left" width="29.400%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo-subtracted mean maximal decrease in systolic blood pressure (mm Hg)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Tadalafil 10 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><span class="Bold">Tadalafil 20 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">3.2 (-2.3, 8.6)
</td>
<td class="Botrule Rrule" align="center" valign="top">3.2 (-2.3, 8.7)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">1.7 (-4.7, 8.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">2.3 (-4.1, 8.7)
</td>
</tr>
</tbody>
</table>
<p>Blood pressure was measured manually at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours after tadalafil or placebo dosing. There were 2, 2, and 1 outliers (subjects with a decrease from baseline in standing systolic blood pressure of &gt;30Â mmÂ Hg at one or more time points) following administration of tadalafil 10Â mg, 20Â mg, and placebo, respectively. There were no subjects with a standing systolic blood pressure &lt;85Â mmÂ Hg. No severe adverse events potentially related to blood-pressure effects were reported. No <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported.</p>
<p>In the second tamsulosin study, healthy subjects (N=39 treated; and 35 completed) received 14 days of once per day dosing of tadalafil 5Â mg or placebo in a two-period crossover design. Daily dosing of tamsulosin 0.4Â mg was added for the last seven days of each period.</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9: Tamsulosin Study 2: Mean Maximal Decrease (95% CI) in Systolic Blood Pressure
</span></caption>
<col align="left" width="37.867%">
<col align="left" width="25.733%">
<col align="left" width="36.400%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Placebo-subtracted mean maximal decrease in systolic blood pressure</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 5 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">Day 1 of 0.4 mg Tamsulosin</span></td>
<td class="Botrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.1 (-2.2, 1.9)
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">0.9 (-1.4, 3.2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"><span class="Bold">Day 7 of 0.4 mg Tamsulosin</span></td>
<td class="Botrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">1.2 (-1.2, 3.6)
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">1.2 (-1.0, 3.5)
</td>
</tr>
</tbody>
</table>
<p>Blood pressure was measured manually pre-dose at two time points (-30 and -15 minutes) and then at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post dose on the first, sixth and seventh days of tamsulosin administration. There were no outliers (subjects with a decrease from baseline in standing systolic blood pressure of &gt;30Â mmÂ Hg at one or more time points). One subject on placebo plus tamsulosin (DayÂ 7) and one subject on tadalafil plus tamsulosin (DayÂ 6) had standing systolic blood pressure &lt;85Â mmÂ Hg. No severe adverse events potentially related to blood pressure were reported. No <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s89"></a><a name="section-11.2.3.3"></a><p></p>
<p class="First"><span class="Italics">Alfuzosin</span> â€” A single oral dose of tadalafil 20Â mg or placebo was administered in a 2-period, crossover design to healthy subjects taking once-daily alfuzosin HCl 10Â mg extended-release tablets, an alpha[1]-adrenergic blocker (N=17 completed subjects). Tadalafil or placebo was administered 4 hours after alfuzosin following a minimum of seven days of alfuzosin dosing.</p>
<a name="t10"></a><table width="100%">
<caption><span>Table 10: Alfuzosin (10Â mg/day) Study: Mean Maximal Decrease (95% CI) in Systolic Blood Pressure
</span></caption>
<col align="left" width="59.800%">
<col align="left" width="40.200%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Placebo-subtracted mean maximal decrease in systolic blood pressure (mm Hg)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tadalafil 20 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="right" valign="top">Supine
</td>
<td class="Botrule Rrule" align="center" valign="top">2.2 (-0.9,-5.2)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="right" valign="top">Standing
</td>
<td class="Botrule Rrule" align="center" valign="top">4.4 (-0.2, 8.9)
</td>
</tr>
</tbody>
</table>
<p>Blood pressure was measured manually at 1, 2, 3, 4, 6, 8, 10, 20, and 24 hours after tadalafil or placebo dosing. There was 1 outlier (subject with a standing systolic blood pressure &lt;85Â mmÂ Hg) following administration of tadalafil 20Â mg. There were no subjects with a decrease from baseline in standing systolic blood pressure of &gt;30Â mmÂ Hg at one or more time points. No severe adverse events potentially related to blood pressure effects were reported. No <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s90"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline">Effects on Blood Pressure When Administered with Antihypertensives</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s91"></a><a name="section-11.2.4.1"></a><p></p>
<p class="First"><span class="Italics">Amlodipine</span> â€” A study was conducted to assess the interaction of amlodipine (5Â mg daily) and tadalafil 10Â mg. There was no effect of tadalafil on amlodipine blood levels and no effect of amlodipine on tadalafil blood levels. The mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10Â mg in subjects taking amlodipine was 3/2Â mmÂ Hg, compared to placebo. In a similar study using tadalafil 20Â mg, there were no clinically significant differences between tadalafil and placebo in subjects taking amlodipine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s92"></a><a name="section-11.2.4.2"></a><p></p>
<p class="First"><span class="Italics">Angiotensin II receptor blockers</span> (with and without other antihypertensives) â€” A study was conducted to assess the interaction of angiotensin II receptor blockers and tadalafil 20Â mg. Subjects in the study were taking any marketed angiotensin II receptor blocker, either alone, as a component of a combination product, or as part of a multiple antihypertensive regimen. Following dosing, ambulatory measurements of blood pressure revealed differences between tadalafil and placebo of 8/4Â mmÂ Hg in systolic/diastolic blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s93"></a><a name="section-11.2.4.3"></a><p></p>
<p class="First"><span class="Italics">Bendrofluazide</span> â€” A study was conducted to assess the interaction of bendrofluazide (2.5Â mg daily) and tadalafil 10Â mg. Following dosing, the mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10Â mg in subjects taking bendrofluazide was 6/4Â mmÂ Hg, compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s94"></a><a name="section-11.2.4.4"></a><p></p>
<p class="First"><span class="Italics">Enalapril</span> â€” A study was conducted to assess the interaction of enalapril (10Â to 20Â mg daily) and tadalafil 10Â mg. Following dosing, the mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10Â mg in subjects taking enalapril was 4/1Â mmÂ Hg, compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s95"></a><a name="section-11.2.4.5"></a><p></p>
<p class="First"><span class="Italics">Metoprolol</span> â€” A study was conducted to assess the interaction of sustained-release metoprolol (25 to 200Â mg daily) and tadalafil 10Â mg. Following dosing, the mean reduction in supine systolic/diastolic blood pressure due to tadalafil 10Â mg in subjects taking metoprolol was 5/3Â mmÂ Hg, compared to placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s96"></a><a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Underline">Effects on Blood Pressure When Administered with Alcohol</span></p>
<p>Alcohol and PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. The interaction of tadalafil with alcohol was evaluated in 3 clinical pharmacology studies. In 2 of these, alcohol was administered at a dose of 0.7Â g/kg, which is equivalent to approximately 6 ounces of 80-proof vodka in an 80-kg male, and tadalafil was administered at a dose of 10Â mg in one study and 20Â mg in another. In both these studies, all patients imbibed the entire alcohol dose within 10Â minutes of starting. In one of these two studies, blood alcohol levels of 0.08% were confirmed. In these two studies, more patients had clinically significant decreases in blood pressure on the combination of tadalafil and alcohol as compared to alcohol alone. Some subjects reported postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> was observed in some subjects. When tadalafil 20Â mg was administered with a lower dose of alcohol (0.6Â g/kg, which is equivalent to approximately 4Â ounces of 80-proof vodka, administered in less than 10 minutes), <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> was not observed, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> occurred with similar frequency to alcohol alone, and the hypotensive effects of alcohol were not potentiated.</p>
<p>Tadalafil did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s97"></a><a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Underline">Effects on Exercise Stress Testing</span></p>
<p>The effects of tadalafil on cardiac function, hemodynamics, and exercise tolerance were investigated in a single clinical pharmacology study. In this blinded crossover trial, 23 subjects with stable <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> and evidence of exercise-induced <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span> were enrolled. The primary endpoint was time to <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>. The mean difference in total exercise time was 3Â seconds (tadalafil 10Â mg minus placebo), which represented no clinically meaningful difference. Further statistical analysis demonstrated that tadalafil was non-inferior to placebo with respect to time to <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. Of note, in this study, in some subjects who received tadalafil followed by sublingual nitroglycerin in the post-exercise period, clinically significant reductions in blood pressure were observed, consistent with the augmentation by tadalafil of the blood-pressure-lowering effects of nitrates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s98"></a><a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Underline">Effects on Vision</span></p>
<p>Single oral doses of phosphodiesterase inhibitors have demonstrated transient dose-related impairment of color discrimination (blue/green), using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. In a study to assess the effects of a singleÂ dose of tadalafil 40Â mg on vision (N=59), no effects were observed on visual acuity, intraocular pressure, or pupilometry. Across all clinical studies with CIALIS, reports of changes in color vision were rare (&lt;0.1% of patients).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s99"></a><a name="section-11.2.8"></a><p></p>
<p class="First"><span class="Underline">Effects on Sperm Characteristics</span></p>
<p>Three studies were conducted in men to assess the potential effect on sperm characteristics of tadalafil 10Â mg (one 6 month study) and 20Â mg (one 6 month and one 9 month study) administered daily. There were no adverse effects on sperm morphology or sperm motility in any of the three studies. In the study of 10Â mg tadalafil for 6 months and the study of 20Â mg tadalafil for 9 months, results showed a decrease in mean sperm concentrations relative to placebo, although these differences were not clinically meaningful. This effect was not seen in the study of 20Â mg tadalafil taken for 6 months. In addition there was no adverse effect on mean concentrations of reproductive hormones, testosterone, luteinizing hormone or follicle stimulating hormone with either 10 or 20Â mg of tadalafil compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s100"></a><a name="section-11.2.9"></a><p></p>
<p class="First"><span class="Underline">Effects on Cardiac Electrophysiology</span></p>
<p>The effect of a single 100-mg dose of tadalafil on the QT interval was evaluated at the time of peak tadalafil concentration in a randomized, double-blinded, placebo, and active (intravenous ibutilide) -controlled crossover study in 90 healthy males aged 18 to 53 years. The mean change in QT<span class="Sub">c</span> (Fridericia QT correction) for tadalafil, relative to placebo, was 3.5Â milliseconds (two-sided 90%Â CI=1.9, 5.1). The mean change in QT<span class="Sub">c</span> (Individual QT correction) for tadalafil, relative to placebo, was 2.8Â millisecondsÂ (two-sided 90%Â CI=1.2, 4.4). A 100-mg dose of tadalafil (5 times the highest recommended dose) was chosen because this dose yields exposures covering those observed upon coadministration of tadalafil with potent CYP3A4 inhibitors or those observed in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In this study, the mean increase in heart rate associated with a 100-mg dose of tadalafil compared to placebo was 3.1 beats per minute.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s101"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Over a dose range of 2.5 to 20Â mg, tadalafil exposure (AUC) increases proportionally with dose in healthy subjects. Steady-state plasma concentrations are attained within 5 days of once per day dosing and exposure is approximately 1.6-fold greater than after a single dose. Mean tadalafil concentrations measured after the administration of a single oral dose of 20Â mg and single and once daily multiple doses of 5Â mg, from a separate study, (<span class="Italics">see </span><a href="#f05">Figure 4</a>) to healthy male subjects are depicted in <a href="#f05">Figure 4</a>.</p>
<div class="Figure">
<a name="f05"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f001-v2.jpg"><p class="MultiMediaCaption">Figure 4: Plasma tadalafil concentrations (mean Â± SD) following a single 20-mg tadalafil dose and single and once daily multiple doses of 5 mg</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s102"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span> â€” After single oral-dose administration, the maximum observed plasma concentration (C<span class="Sub">max</span>) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined.</p>
<p>The rate and extent of absorption of tadalafil are not influenced by food; thus CIALIS may be taken with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s103"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span> â€” The mean apparent volume of distribution following oral administration is approximately 63Â L, indicating that tadalafil is distributed into tissues. At therapeutic concentrations, 94% of tadalafil in plasma is bound to proteins.</p>
<p>Less than 0.0005% of the administered dose appeared in the semen of healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s104"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span> â€” Tadalafil is predominantly metabolized by CYP3A4 to a catechol metabolite. The catechol metabolite undergoes extensive methylation and glucuronidation to form the methylcatechol and methylcatechol glucuronide conjugate, respectively. The major circulating metabolite is the methylcatechol glucuronide. Methylcatechol concentrations are less than 10% of glucuronide concentrations. <span class="Italics">InÂ vitro</span> data suggests that metabolites are not expected to be pharmacologically active at observed metabolite concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s105"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Excretion</span> â€” The mean oral clearance for tadalafil is 2.5Â L/hr and the mean terminal half-life is 17.5 hours in healthy subjects. Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s106"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Geriatric</span> â€” Healthy male elderly subjects (65 years or over) had a lower oral clearance of tadalafil, resulting in 25% higher exposureÂ (AUC) with no effect on C<span class="Sub">max</span> relative to that observed in healthy subjects 19 to 45 years of age. No dose adjustment is warranted based on age alone. However, greater sensitivity to medications in some older individuals should be considered <span class="Italics">[see Use in Specific Populations (<a href="#s76">8.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s107"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Pediatric</span> â€” Tadalafil has not been evaluated in individuals less than 18 years old <span class="Italics">[see Use in Specific Populations (<a href="#s75">8.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s108"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Underline">Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span> â€” In male patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus after a 10Â mg tadalafil dose, exposure (AUC) was reduced approximately 19% and C<span class="Sub">max</span> was 5% lower than that observed in healthy subjects. No dose adjustment is warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s108a"></a><a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Underline">Patients with BPH</span> â€” In patients with BPH following single and multiple-doses of 20Â mg tadalafil, no statistically significant differences in exposure (AUC and C<span class="Sub">max</span>) were observed between elderly (70 to 85 years) and younger (â‰¤60 years of age) subjects. No dose adjustment is warranted.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s109"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s110"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s110a"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span> â€” Tadalafil was not carcinogenic to rats or mice when administered daily for 2 years at doses up to 400Â mg/kg/day. Systemic drug exposures, as measured by AUC of unbound tadalafil, were approximately 10-fold for mice, and 14- and 26-fold for male and femaleÂ rats, respectively, the exposures in human males given Maximum Recommended Human Dose (MRHD) of 20Â mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s110b"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span> â€” Tadalafil was not mutagenic in the <span class="Italics">inÂ vitro</span> bacterial Ames assays or the forward mutation test in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. Tadalafil was not clastogenic in the <span class="Italics">inÂ vitro</span> chromosomal aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or the <span class="Italics">inÂ vivo</span> rat micronucleus assays.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s110c"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span> â€” There were no effects on fertility, reproductive performance or reproductive organ morphology in male or female rats given oral doses of tadalafil up to 400Â mg/kg/day, a dose producing AUCs for unbound tadalafil of 14-fold for males or 26-fold for females the exposures observed in human males given the MRHD of 20Â mg. In beagleÂ dogs given tadalafil daily for 3 to 12 months, there was treatment-related non-reversible degeneration and <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> of the seminiferous tubular epithelium in the testes in 20-100% of the dogs that resulted in a decrease in spermatogenesis in 40-75% of the dogs at doses of â‰¥10Â mg/kg/day. Systemic exposure (based on AUC) at no-observed-adverse-effect-level (NOAEL) (10Â mg/kg/day) for unbound tadalafil was similar to that expected in humans at the MRHD of 20Â mg.</p>
<p>There were no treatment-related testicular findings in rats or mice treated with doses up to 400Â mg/kg/day for 2 years.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s111"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Animal studies showed vascular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in tadalafil-treated mice, rats, and dogs. In mice and rats, lymphoid <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> were seen in the spleen, thymus, and mesenteric lymph nodes at unbound tadalafil exposure of 2- to 33-fold above the human exposure (AUCs) at the MRHD of 20Â mg. In dogs, an increased incidence of disseminated <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span> was observed in 1- and 6-month studies at unbound tadalafil exposure of 1- to 54-fold above the human exposure (AUC) at the MRHD of 20Â mg. In a 12-month dog study, no disseminated <span class="product-label-link" type="condition" conceptid="314659" conceptname="Arteritis">arteritis</span> was observed, but 2 dogs exhibited marked decreases in white blood cells (<span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>) and moderate decreases in platelets with inflammatory signs at unbound tadalafil exposures of approximately 14- to 18-fold the human exposure at the MRHD of 20Â mg. The abnormal blood-cell findings were reversible within 2 weeks after stopping treatment.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s113"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s114"></a><a name="section-13.1"></a><p></p>
<h2>14.1 CIALIS for Use as Needed for ED</h2>
<p class="First">The efficacy and safety of tadalafil in the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> has been evaluated in 22 clinical trials of up to 24-weeks duration, involving over 4000 patients. CIALIS, when taken as needed up to once per day, was shown to be effective in improving erectile function in men with <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (ED).</p>
<p>CIALIS was studied in the general ED population in 7 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12-weeks duration. Two of these studies were conducted in the United States and 5 were conducted in centers outside the US. Additional efficacy and safety studies were performed in ED patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and in patients who developed ED status post bilateral nerve-sparing radical prostatectomy.
</p>
<p>In these 7 trials, CIALIS was taken as needed, at doses ranging from 2.5 to 20Â mg, up to once per day. Patients were free to choose the time interval between dose administration and the time of sexual attempts. Food and alcohol intake were not restricted.</p>
<p>Several assessment tools were used to evaluate the effect of CIALIS on erectile function. The 3 primary outcome measures were the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) and QuestionsÂ 2 and 3 from Sexual Encounter Profile (SEP). The IIEF is a 4-week recall questionnaire that was administered at the end of a treatment-free baseline period and subsequently at follow-up visits after randomization. The IIEF EF domain has a 30-point total score, where higher scores reflect better erectile function. SEP is a diary in which patients recorded each sexual attempt made throughout the study. SEP QuestionÂ 2 asks, â€œWere you able to insert your penis into the partner's vagina?â€? SEP QuestionÂ 3 asks, â€œDid your erection last long enough for you to have successful intercourse?â€? The overall percentage of successful attempts to insert the penis into the vagina (SEP2) and to maintain the erection for successful intercourse (SEP3) is derived for each patient.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s115"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Underline">Results in ED Population in US Trials</span> â€” The 2 primary US efficacy and safety trials included a total of 402 men with <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, with a mean age of 59 years (range 27 to 87 years). The population was 78% White, 14% Black, 7% Hispanic, and 1%Â of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease. Most (&gt;90%) patients reported ED of at least 1-year duration. StudyÂ A was conducted primarily in academic centers. StudyÂ B was conducted primarily in community-based urology practices. In each of these 2 trials, CIALIS 20Â mg showed clinically meaningful and statistically significant improvements in all 3 primary efficacy variables (<span class="Italics">see </span><a href="#t11">Table 11</a>). The treatment effect of CIALIS did not diminish over time.</p>
<a name="t11"></a><table width="100%">
<caption><span>Table 11: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two Primary US Trials
</span></caption>
<col align="left" width="28.814%">
<col align="left" width="12.343%">
<col align="left" width="12.043%">
<col align="left" width="11.357%">
<col align="left" width="12.043%">
<col align="left" width="12.043%">
<col align="left" width="11.357%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Study A</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Study B</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">CIALIS</span><br><span class="Bold">20 mg</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">CIALIS</span><br><span class="Bold">20 mg</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=49)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=146)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=48)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=159)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"><span class="Bold">EF Domain Score</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="top">13.5
</td>
<td class="Botrule Rrule" align="center" valign="top">19.5
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">13.6
</td>
<td class="Botrule Rrule" align="center" valign="top">22.5
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="top">-0.2
</td>
<td class="Botrule Rrule" align="center" valign="top">6.9
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="top">0.3
</td>
<td class="Botrule Rrule" align="center" valign="top">9.3
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"><span class="Bold">Insertion of Penis (SEP2)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="top">39%
</td>
<td class="Botrule Rrule" align="center" valign="top">62%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">43%
</td>
<td class="Botrule Rrule" align="center" valign="top">77%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">26%
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="top">2%
</td>
<td class="Botrule Rrule" align="center" valign="top">32%
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"><span class="Bold">Maintenance of Erection (SEP3)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="top">25%
</td>
<td class="Botrule Rrule" align="center" valign="top">50%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">23%
</td>
<td class="Botrule Rrule" align="center" valign="top">64%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="top">5%
</td>
<td class="Botrule Rrule" align="center" valign="top">34%
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="top">4%
</td>
<td class="Botrule Rrule" align="center" valign="top">44%
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s116"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Underline">Results in General ED Population in Trials Outside the US</span> â€” The 5 primary efficacy and safety studies conducted in the general ED population outside the US included 1112 patients, with a mean age of 59 years (range 21 to 82 years). The population was 76% White, 1% Black, 3% Hispanic, and 20% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease. Most (90%) patients reported ED of at least 1-year duration. In these 5 trials, CIALIS 5, 10, and 20Â mg showed clinically meaningful and statistically significant improvements in all 3 primary efficacy variables (<span class="Italics">see </span><a href="#t12">Tables 12</a>, <a href="#t13">13</a> and <a href="#t14">14</a>). The treatment effect of CIALIS did not diminish over time.</p>
<a name="t12"></a><table width="100%">
<caption><span>Table 12: Mean Endpoint and Change from Baseline for the EF Domain of the IIEF in the General ED Population in Five Primary Trials Outside the US
</span></caption>
<col align="left" width="37.840%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Treatment duration in Study F was 6 months
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>10 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>20 mg</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study C</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">15.0 [0.7]
</td>
<td class="Botrule Rrule" align="center" valign="top">17.9 [4.0]
</td>
<td class="Botrule Rrule" align="center" valign="top">20.0 [5.6]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p=.006</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study D</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">14.4 [1.1]
</td>
<td class="Botrule Rrule" align="center" valign="top">17.5 [5.1]
</td>
<td class="Botrule Rrule" align="center" valign="top">20.6 [6.0]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p=.002</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study E</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">18.1 [2.6]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">22.6 [8.1]
</td>
<td class="Botrule Rrule" align="center" valign="top">25.0 [8.0]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study F<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">12.7 [-1.6]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">22.8 [6.8]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study G</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">14.5 [-0.9]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">21.2 [6.6]
</td>
<td class="Botrule Rrule" align="center" valign="top">23.3 [8.0]
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
</tbody>
</table>
<a name="t13"></a><table width="100%">
<caption><span>Table 13: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 2 (â€œWere you able to insert your penis into the partner's vagina?â€?) in the General ED Population in Five Pivotal Trials Outside the US
</span></caption>
<col align="left" width="37.840%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Treatment duration in Study F was 6 months
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>10 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>20 mg</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study C</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">49% [6%]
</td>
<td class="Botrule Rrule" align="center" valign="top">57% [15%]
</td>
<td class="Botrule Rrule" align="center" valign="top">73% [29%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p=.063</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study D</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">46% [2%]
</td>
<td class="Botrule Rrule" align="center" valign="top">56% [18%]
</td>
<td class="Botrule Rrule" align="center" valign="top">68% [15%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p=.008</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study E</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">55% [10%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">77% [35%]
</td>
<td class="Botrule Rrule" align="center" valign="top">85% [35%]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study F<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">42% [-8%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">81% [27%]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study G</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">45% [-6%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">73% [21%]
</td>
<td class="Botrule Rrule" align="center" valign="top">76% [21%]
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
</tbody>
</table>
<a name="t14"></a><table width="100%">
<caption><span>Table 14: Mean Post-Baseline Success Rate and Change from Baseline for SEP Question 3 (â€œDid your erection last long enough for you to have successful intercourse?â€?) in the General ED Population in Five Pivotal Trials Outside the US
</span></caption>
<col align="left" width="37.840%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Treatment duration in Study F was 6 months
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>10 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>20 mg</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study C</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">26% [4%]
</td>
<td class="Botrule Rrule" align="center" valign="top">38% [19%]
</td>
<td class="Botrule Rrule" align="center" valign="top">58% [32%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p=.040</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study D</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">28% [4%]
</td>
<td class="Botrule Rrule" align="center" valign="top">42% [24%]
</td>
<td class="Botrule Rrule" align="center" valign="top">51% [26%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study E</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">43% [15%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">70% [48%]
</td>
<td class="Botrule Rrule" align="center" valign="top">78% [50%]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study F<span class="Sup">a</span></span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">27% [1%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">74% [40%]
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Study G</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">32% [5%]
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">57% [33%]
</td>
<td class="Botrule Rrule" align="center" valign="top">62% [29%]
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">p&lt;.001</span></td>
</tr>
</tbody>
</table>
<p>In addition, there were improvements in EF domain scores, success rates based upon SEP QuestionsÂ 2 and 3, and patient-reported improvement in erections across patients with ED of all degrees of disease severity while taking CIALIS, compared to patients on placebo.</p>
<p>Therefore, in all 7 primary efficacy and safety studies, CIALIS showed statistically significant improvement in patients' ability to achieve an erection sufficient for vaginal penetration and to maintain the erection long enough for successful intercourse, as measured by the IIEF questionnaire and by SEP diaries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s117"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Underline">Efficacy Results in ED Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span> â€” CIALIS was shown to be effective in treating ED in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were included in all 7 primary efficacy studies in the general ED population (N=235) and in one study that specifically assessed CIALIS in EDÂ patients with typeÂ 1 or typeÂ 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (N=216). In this randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial, CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and QuestionsÂ 2 and 3 of the SEP diary (<span class="Italics">see </span><a href="#t15">Table 15</a>).</p>
<a name="t15"></a><table width="100%">
<caption><span>Table 15: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in ED Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>
</span></caption>
<col align="left" width="37.840%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<col align="left" width="15.540%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>10 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>20 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=71)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=73)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=72)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">EF Domain Score</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">12.2 [0.1]
</td>
<td class="Botrule Rrule" align="center" valign="top">19.3 [6.4]
</td>
<td class="Botrule Rrule" align="center" valign="top">18.7 [7.3]
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Insertion of PenisÂ (SEP2)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">30% [-4%]
</td>
<td class="Botrule Rrule" align="center" valign="top">57% [22%]
</td>
<td class="Botrule Rrule" align="center" valign="top">54% [23%]
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Maintenance of ErectionÂ (SEP3)</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="top">20% [2%]
</td>
<td class="Botrule Rrule" align="center" valign="top">48% [28%]
</td>
<td class="Botrule Rrule" align="center" valign="top">42% [29%]
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s118"></a><a name="section-13.1.4"></a><p></p>
<p class="First"><span class="Underline">Efficacy Results in ED Patients following Radical Prostatectomy</span> â€” CIALIS was shown to be effective in treating patients who developed ED following bilateral nerve-sparing radical prostatectomy. In 1 randomized, placebo-controlled, double-blinded, parallel-arm design prospective trial in this population (N=303), CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EFÂ domain of the IIEF questionnaire and QuestionsÂ 2 and 3 of the SEP diary (<span class="Italics">see </span><a href="#t16">Table 16</a>).</p>
<a name="t16"></a><table width="100%">
<caption><span>Table 16: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a Study in Patients who Developed ED Following Bilateral Nerve-Sparing Radical Prostatectomy
</span></caption>
<col align="left" width="37.850%">
<col align="left" width="19.425%">
<col align="left" width="19.425%">
<col align="left" width="23.300%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>20 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=102)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=201)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">EF Domain Score</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="middle">13.3 [1.1]
</td>
<td class="Botrule Rrule" align="center" valign="middle">17.7 [5.3]
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">Insertion of Penis (SEP2)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="middle">32% [2%]
</td>
<td class="Botrule Rrule" align="center" valign="middle">54% [22%]
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">Maintenance of Erection (SEP3)</span></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint [Change from baseline]
</td>
<td class="Botrule Rrule" align="center" valign="middle">19% [4%]
</td>
<td class="Botrule Rrule" align="center" valign="middle">41% [23%]
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s119"></a><a name="section-13.1.5"></a><p></p>
<p class="First"><span class="Underline">Results in Studies to Determine the Optimal Use of CIALIS</span> â€” Several studies were conducted with the objective of determining the optimal use of CIALIS in the treatment of ED. In one of these studies, the percentage of patients reporting successful erections within 30 minutes of dosing was determined. In this randomized, placebo-controlled, double-blinded trial, 223 patients were randomized to placebo, CIALIS 10, or 20Â mg. Using a stopwatch, patients recorded the time following dosing at which a successful erection was obtained. A successful erection was defined as at least 1 erection in 4 attempts that led to successful intercourse. At or prior to 30 minutes, 35% (26/74), 38% (28/74), and 52% (39/75) of patients in the placebo, 10-, and 20-mg groups, respectively, reported successful erections as defined above.</p>
<p>Two studies were conducted to assess the efficacy of CIALIS at a given timepoint after dosing, specifically at 24 hours and at 36 hours after dosing.</p>
<p>In the first of these studies, 348 patients with ED were randomized to placebo or CIALIS 20Â mg. Patients were encouraged to make 4 total attempts at intercourse; 2 attempts were to occur at 24 hours after dosing and 2 completely separate attempts were to occur at 36 hours after dosing. The results demonstrated a difference between the placebo group and the CIALIS group at each of the pre-specified timepoints. At the 24-hour timepoint, (more specifically, 22 to 26 hours), 53/144 (37%) patients reported at least 1Â successful intercourse in the placebo group versus 84/138 (61%) in the CIALIS 20-mg group. At the 36-hour timepoint (more specifically, 33 to 39 hours), 49/133 (37%) of patients reported at least 1 successful intercourse in the placebo group versus 88/137 (64%) in the CIALIS 20-mg group.</p>
<p>In the second of these studies, a total of 483 patients were evenly randomized to 1 of 6 groups: 3 different dosing groups (placebo, CIALIS 10, or 20 mg) that were instructed to attempt intercourse at 2 different times (24 and 36 hours post-dosing). Patients were encouraged to make 4 separate attempts at their assigned dose and assigned timepoint. In this study, the results demonstrated a statistically significant difference between the placebo group and the CIALIS groups at each of the pre-specified timepoints. At the 24-hour timepoint, the mean, per patient percentage of attempts resulting in successful intercourse were 42, 56, and 67% for the placebo, CIALIS 10-, and 20-mg groups, respectively. At the 36-hour timepoint, the mean, per-patient percentage of attempts resulting in successful intercourse were 33, 56, and 62% for placebo, CIALIS 10-, and 20-mg groups, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s120"></a><a name="section-13.2"></a><p></p>
<h2>14.2 CIALIS for Once Daily Use for ED</h2>
<p class="First">The efficacy and safety of CIALIS for once daily use in the treatment of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> has been evaluated in 2 clinical trials of 12-weeks duration and 1 clinical trial of 24-weeks duration, involving a total of 853 patients. CIALIS, when taken once daily, was shown to be effective in improving erectile function in men with <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (ED).</p>
<p>CIALIS was studied in the general ED population in 2 randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design, primary efficacy and safety studies of 12- and 24-weeks duration, respectively. One of these studies was conducted in the United States and one was conducted in centers outside the US. An additional efficacy and safety study was performed in ED patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. CIALIS was taken once daily at doses ranging from 2.5 to 10Â mg. Food and alcohol intake were not restricted. Timing of sexual activity was not restricted relative to when patients took Cialis.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s121"></a><a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Underline">Results in General ED Population</span> â€” The primary US efficacy and safety trial included a total of 287 patients, with a mean age of 59 years (range 25 to 82 years). The population was 86% White, 6% Black, 6% Hispanic, and 2% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease. Most (&gt;96%) patients reported ED of at least 1-year duration.</p>
<p>The primary efficacy and safety study conducted outside the US included 268 patients, with a mean age of 56 years (range 21 to 78 years). The population was 86% White, 3% Black, 0.4% Hispanic, and 10% of other ethnicities, and included patients with ED of various severities, etiologies (organic, psychogenic, mixed), and with multiple co-morbid conditions, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease. Ninety-three percent of patients reported ED of at least 1-year duration.</p>
<p>In each of these trials, conducted without regard to the timing of dose and sexual intercourse, CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (<span class="Italics">see </span><a href="#t17">Table 17</a>). When taken as directed, CIALIS was effective at improving erectile function.</p>
<p>In the 6 month double-blind study, the treatment effect of CIALIS did not diminish over time.</p>
<a name="t17"></a><table width="100%">
<caption><span>Table 17: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in the Two CIALIS for Once Daily Use Studies
</span></caption>
<col align="left" width="29.550%">
<col align="left" width="9.750%">
<col align="left" width="10.188%">
<col align="left" width="10.188%">
<col align="left" width="8.875%">
<col align="left" width="11.238%">
<col align="left" width="11.200%">
<col align="left" width="9.012%">
<tfoot>
<tr class="First"><td align="left" colspan="8" valign="top"><p class="First Footnote"><span class="Sup">a</span> Twenty-four-week study conducted in the US.
</p></td></tr>
<tr><td align="left" colspan="8" valign="top"><p class="First Footnote"><span class="Sup">b</span> Twelve-week study conducted outside the US.
</p></td></tr>
<tr class="Last"><td align="left" colspan="8" valign="top"><p class="First Footnote"><span class="Sup">c</span> Statistically significantly different from placebo.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle"><span class="Bold">Study H<span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">Study I<span class="Sup">b</span></span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">CIALIS<br>2.5 mg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">CIALIS<br>5 mg</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">CIALIS<br>5 mg</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(N=94)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(N=96)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(N=97)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">p-value</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(N=54)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">(N=109)</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">p-value</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top"><span class="Bold">EF Domain Score</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="middle">14.6
</td>
<td class="Botrule Rrule" align="center" valign="middle">19.1
</td>
<td class="Botrule Rrule" align="center" valign="middle">20.8
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">15.0
</td>
<td class="Botrule Rrule" align="center" valign="middle">22.8
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.2
</td>
<td class="Botrule Rrule" align="center" valign="middle">6.1<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">7.0<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="middle">0.9
</td>
<td class="Botrule Rrule" align="center" valign="middle">9.7<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top"><span class="Bold">Insertion of Penis (SEP2)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="middle">51%
</td>
<td class="Botrule Rrule" align="center" valign="middle">65%
</td>
<td class="Botrule Rrule" align="center" valign="middle">71%
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">52%
</td>
<td class="Botrule Rrule" align="center" valign="middle">79%
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="middle">5%
</td>
<td class="Botrule Rrule" align="center" valign="middle">24%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">26%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="middle">11%
</td>
<td class="Botrule Rrule" align="center" valign="middle">37%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top"><span class="Bold">Maintenance of Erection (SEP3)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="middle">31%
</td>
<td class="Botrule Rrule" align="center" valign="middle">50%
</td>
<td class="Botrule Rrule" align="center" valign="middle">57%
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle">37%
</td>
<td class="Botrule Rrule" align="center" valign="middle">67%
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="middle">10%
</td>
<td class="Botrule Rrule" align="center" valign="middle">31%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">35%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="middle">13%
</td>
<td class="Botrule Rrule" align="center" valign="middle">46%<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s122"></a><a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Underline">Efficacy Results in ED Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span> â€” CIALIS for once daily use was shown to be effective in treating ED in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were included in both studies in the general ED population (N=79). A third randomized, multicenter, double-blinded, placebo-controlled, parallel-arm design trial included only ED patients with type 1 or type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (N=298). In this third trial, CIALIS demonstrated clinically meaningful and statistically significant improvement in erectile function, as measured by the EF domain of the IIEF questionnaire and Questions 2 and 3 of the SEP diary (<span class="Italics">see </span><a href="#t18">Table 18</a>).</p>
<a name="t18"></a><table width="100%">
<caption><span>Table 18: Mean Endpoint and Change from Baseline for the Primary Efficacy Variables in a CIALIS for Once Daily Use Study in ED Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>
</span></caption>
<col align="left" width="59.140%">
<col align="left" width="10.220%">
<col align="left" width="10.680%">
<col align="left" width="10.680%">
<col align="left" width="9.280%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> Statistically significantly different from placebo.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>2.5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">CIALIS<br>5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=100)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=100)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">(N=98)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">p-value</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">EF Domain Score</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="middle">14.7
</td>
<td class="Botrule Rrule" align="center" valign="middle">18.3
</td>
<td class="Botrule Rrule" align="center" valign="middle">17.2
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="middle">1.3
</td>
<td class="Botrule Rrule" align="center" valign="middle">4.8<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">4.5<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Insertion of Penis (SEP2)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="middle">43%
</td>
<td class="Botrule Rrule" align="center" valign="middle">62%
</td>
<td class="Botrule Rrule" align="center" valign="middle">61%
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="middle">5%
</td>
<td class="Botrule Rrule" align="center" valign="middle">21%<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">29%<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><span class="Bold">Maintenance of Erection (SEP3)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="middle">28%
</td>
<td class="Botrule Rrule" align="center" valign="middle">46%
</td>
<td class="Botrule Rrule" align="center" valign="middle">41%
</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from baseline
</td>
<td class="Botrule Rrule" align="center" valign="middle">8%
</td>
<td class="Botrule Rrule" align="center" valign="middle">26%<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">25%<span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle">&lt;.001
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s122a"></a><a name="section-13.3"></a><p></p>
<h2>14.3 CIALIS 5Â mg for Once Daily Use for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span> (BPH)
</h2>
<p class="First">The efficacy and safety of CIALIS for once daily use for the treatment of the signs and symptoms of BPH was evaluated in 3 randomized, multinational, double-blinded, placebo-controlled, parallel-design, efficacy and safety studies of 12 weeks duration. Two of these studies were in men with BPH and one study was specific to men with both ED and BPH <span class="Italics">[see Clinical Studies (<a href="#s122b">14.4</a>)]</span>. The first study (Study J) randomized 1058 patients to receive either CIALIS 2.5Â mg, 5Â mg, 10Â mg or 20Â mg for once daily use or placebo. The second study (Study K) randomized 325Â patients to receive either CIALIS 5Â mg for once daily use or placebo. The full study population was 87% White, 2% Black, 11% other races; 15% was of Hispanic ethnicity. Patients with multiple co-morbid conditions such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease were included.
</p>
<p>The primary efficacy endpoint in the two studies that evaluated the effect of CIALIS for the signs and symptoms of BPH was the International Prostate Symptom Score (IPSS), a four week recall questionnaire that was administered at the beginning and end of a placebo run-in period and subsequently at follow-up visits after randomization. The IPSS assesses the severity of irritative (frequency, urgency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>) and obstructive symptoms (incomplete emptying, stopping and starting, weak stream, and pushing or straining), with scores ranging from 0 to 35; higher numeric scores representing greater severity. Maximum urinary flow rate (Q<span class="Sub">max</span>), an objective measure of urine flow, was assessed as a secondary efficacy endpoint in Study J and as a safety endpoint in Study K.
</p>
<p>The results for BPH patients with moderate to severe symptoms and a mean age of 63.2 years (range 44 to 87) who received either CIALIS 5Â mg for once daily use or placebo (N=748) in Studies J and K are shown in <a href="#t19">Table 19</a> and <a href="#f06">Figures 5</a> and <a href="#f07">6</a>, respectively.
</p>
<p>In each of these 2 trials, CIALIS 5Â mg for once daily use resulted in statistically significant improvement in the total IPSS compared to placebo. Mean total IPSS showed a decrease starting at the first scheduled observation (4 weeks) in Study K and remained decreased through 12 weeks.
</p>
<a name="t19"></a><table width="100%">
<caption><span>
Table 19: Mean IPSS Changes in BPH Patients in Two CIALIS for Once Daily Use Studies
</span></caption>
<col align="left" width="33.324%">
<col align="left" width="12.498%">
<col align="left" width="11.670%">
<col align="left" width="9.999%">
<col align="left" width="11.670%">
<col align="left" width="11.670%">
<col align="left" width="9.170%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="3" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">
Study J
</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><span class="Bold">
Study K
</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
Placebo
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
CIALIS<br>5 mg
</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
Placebo
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
CIALIS<br>5 mg
</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
(N=205)
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
(N=205)
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
p-value
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
(N=164)
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
(N=160)
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
p-value
</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"><span class="Bold">
Total Symptom Score (IPSS)
</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Â  Â  Â  Baseline
</td>
<td class="Botrule Rrule" align="center" valign="top">
17.1
</td>
<td class="Botrule Rrule" align="center" valign="top">
17.3
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
16.6
</td>
<td class="Botrule Rrule" align="center" valign="top">
17.1
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
Â  Â  Â  Change from Baseline to Week 12
</td>
<td class="Botrule Rrule" align="center" valign="top">
-2.2
</td>
<td class="Botrule Rrule" align="center" valign="top">
-4.8
</td>
<td class="Botrule Rrule" align="center" valign="top">
&lt;.001
</td>
<td class="Botrule Rrule" align="center" valign="top">
-3.6
</td>
<td class="Botrule Rrule" align="center" valign="top">
-5.6
</td>
<td class="Botrule Rrule" align="center" valign="top">
.004
</td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="f06"></a><img alt="Figure 5
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f005-v1.jpg"><p class="MultiMediaCaption">Figure 5: Mean IPSS Changes in BPH Patients by Visit in Study J
</p>
</div>
<div class="Figure">
<a name="f07"></a><img alt="Figure 6
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f006-v1.jpg"><p class="MultiMediaCaption">Figure 6: Mean IPSS Changes in BPH Patients by Visit in Study K
</p>
</div>
<p>In Study J, the effect of CIALIS 5Â mg once daily on maximum urinary flow rate (Q<span class="Sub">max</span>) was evaluated as a secondary efficacy endpoint. Mean Q<span class="Sub">max</span> increased from baseline in both the treatment and placebo groups (CIALIS 5Â mg: 1.6Â mL/sec, placebo: 1.2Â mL/sec); however, these changes were not significantly different between groups.
</p>
<p>In Study K, the effect of CIALIS 5Â mg once daily on Q<span class="Sub">max</span> was evaluated as a safety endpoint. Mean Q<span class="Sub">max</span> increased from baseline in both the treatment and placebo groups (CIALIS 5Â mg: 1.6Â mL/sec, placebo: 1.1Â mL/sec); however, these changes were not significantly different between groups.
</p>
<p><span class="Underline">Efficacy Results in Patients with BPH initiating CIALIS and Finasteride</span> â€“ CIALIS for once daily use initiated together with finasteride was shown to be effective in treating the signs and symptoms of BPH in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> (&gt;30 cc) for up to 26 weeks. This additional double-blinded, parallel-design study of 26 weeks duration randomized 696 men to initiate either CIALIS 5 mg with finasteride 5 mg or placebo with finasteride 5 mg. The study population had a mean age of 64 years (range 46-86). Patients with multiple co-morbid conditions such as <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease were included.</p>
<p>CIALIS with finasteride demonstrated statistically significant improvement in the signs and symptoms of BPH compared to placebo with finasteride, as measured by the total IPSS at 12 weeks, the primary study endpoint (<span class="Italics">see</span> Table 20). Key secondary endpoints demonstrated improvement in total IPSS starting at the first scheduled observation at week 4 (CIALIS -4.0, placebo -2.3: p&lt;.001) and the score remained decreased through 26 weeks (CIALIS -5.5, placebo -4.5; p=.022). However, the magnitude of the treatment difference between placebo/finasteride and CIALIS/finasteride decreased from 1.7 points at Week 4 to 1.0 point at Week 26, as shown in <a href="#t20">Table 20</a> and in <a href="#f09">Figure 7</a>. The incremental benefit of CIALIS beyond 26 weeks is unknown.</p>
<a name="t20"></a><table width="100%">
<caption><span>Table 20: Mean Total IPSS Changes in BPH Patients in a CIALIS for Once Daily Use Study Together with Finasteride
</span></caption>
<col align="left" width="32.750%">
<col align="left" width="8.625%">
<col align="left" width="15.875%">
<col align="left" width="8.750%">
<col align="left" width="15.875%">
<col align="left" width="15.750%">
<col align="left" width="19.750%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">a</span> Overall ITT population.
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">b</span> Mixed model for repeated measurements.
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">c</span> Unadjusted mean.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="1" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Placebo and finasteride 5 mg</span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="1" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">CIALIS 5mg and finasteride 5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Treatment difference</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">(N=350)</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">n</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">(N=345)</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">p-value<span class="Sup">b</span></span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top"><span class="Bold">Total Symptom Score (IPSS)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Baseline<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">349
</td>
<td class="Botrule Rrule" align="center" valign="top">17.4
</td>
<td class="Botrule Rrule" align="center" valign="top">344</td>
<td class="Botrule Rrule" align="center" valign="top">17.1</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Change from Baseline to Week 4<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">340
</td>
<td class="Botrule Rrule" align="center" valign="top">-2.3
</td>
<td class="Botrule Rrule" align="center" valign="top">330
</td>
<td class="Botrule Rrule" align="center" valign="top">-4.0
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.7
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;.001
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Change from Baseline to Week 12<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">318
</td>
<td class="Botrule Rrule" align="center" valign="top">-3.8
</td>
<td class="Botrule Rrule" align="center" valign="top">317
</td>
<td class="Botrule Rrule" align="center" valign="top">-5.2
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.4
</td>
<td class="Botrule Rrule" align="center" valign="top">.001
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â Change from Baseline to Week 26<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">295
</td>
<td class="Botrule Rrule" align="center" valign="top">-4.5
</td>
<td class="Botrule Rrule" align="center" valign="top">308
</td>
<td class="Botrule Rrule" align="center" valign="top">-5.5
</td>
<td class="Botrule Rrule" align="center" valign="top">-1.0
</td>
<td class="Botrule Rrule" align="center" valign="top">.022
</td>
</tr>
</tbody>
</table>
<div class="Figure">
<a name="f09"></a><img alt="Figure 7
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f007-v2.jpg"><p class="MultiMediaCaption">Figure 7: Mean Total IPSS Changes By Visit in BPH Patients Taking CIALIS for Once Daily Use Together With Finasteride
</p>
</div>
<p>In the 404 patients who had both ED and BPH at baseline, changes in erectile function were assessed as key secondary endpoints using the EF domain of the IIEF questionnaire. CIALIS with finasteride (N=203) was compared to placebo with finasteride (N=201). A statistically significant improvement from baseline (CIALIS/finasterideÂ 13.7, placebo/finasterideÂ 15.1) was observed at week 4 (CIALIS/finasterideÂ 3.7, placebo/finasterideÂ -1.1; p&lt;.001), weekÂ 12 (CIALIS/finasterideÂ 4.7, placebo/finasterideÂ 0.6; p&lt;.001), and weekÂ 26 (CIALIS/finasterideÂ 4.7, placebo/finasterideÂ 0.0; p&lt;.001).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s122b"></a><a name="section-13.4"></a><p></p>
<h2>14.4 CIALIS 5Â mg for Once Daily Use for ED and BPH
</h2>
<p class="First">The efficacy and safety of CIALIS for once daily use for the treatment of ED, and the signs and symptoms of BPH, in patients with both conditions was evaluated in one placebo-controlled, multinational, double-blind, parallel-arm study which randomized 606 patients to receive either CIALIS 2.5Â mg, 5Â mg, for once daily use or placebo. ED severity ranged from mild to severe and BPH severity ranged from moderate to severe. The full study population had a mean age of 63 years (range 45 to 83) and was 93% White, 4% Black, 3% other races; 16% were of Hispanic ethnicity. Patients with multiple co-morbid conditions such as <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and other cardiovascular disease were included.
</p>
<p>In this study, the co-primary endpoints were total IPSS and the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF). One of the key secondary endpoints in this study was Question 3 of the Sexual Encounter Profile diary (SEP3). Timing of sexual activity was not restricted relative to when patients took CIALIS.
</p>
<p>The efficacy results for patients with both ED and BPH, who received either CIALIS 5Â mg for once daily use or placebo (N=408) are shown in <a href="#t21">Tables 21</a> and <a href="#t22">22</a> and <a href="#f08">Figure 8</a>.
</p>
<p>CIALIS 5Â mg for once daily use resulted in statistically significant improvements in the total IPSS and in the EF domain of the IIEF questionnaire. CIALIS 5Â mg for once daily use also resulted in statistically significant improvement in SEP3. CIALIS 2.5Â mg did not result in statistically significant improvement in the total IPSS.
</p>
<a name="t21"></a><table width="100%">
<caption><span>Table 21: Mean IPSS and IIEF EF Domain Changes in the CIALIS 5Â mg for Once Daily Use Study in Patients withÂ EDÂ andÂ BPH
</span></caption>
<col align="left" width="39.175%">
<col align="left" width="17.500%">
<col align="left" width="22.500%">
<col align="left" width="20.825%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">Placebo</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">CIALIS 5 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">p-value</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">Total Symptom Score (IPSS)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">(N=193)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">(N=206)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Baseline
</td>
<td class="Botrule Rrule" align="center" valign="bottom">18.2
</td>
<td class="Botrule Rrule" align="center" valign="bottom">18.5
</td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from Baseline to Week 12
</td>
<td class="Botrule Rrule" align="center" valign="bottom">-3.8
</td>
<td class="Botrule Rrule" align="center" valign="bottom">-6.1
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;.001
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">EF Domain Score (IIEF EF)</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">(N=188)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">(N=202)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Baseline
</td>
<td class="Botrule Rrule" align="center" valign="bottom">15.6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">16.5
</td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="bottom">17.6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">22.9
</td>
<td class="Botrule Rrule" align="center" valign="bottom"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â  Change from Baseline to Week 12
</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.9
</td>
<td class="Botrule Rrule" align="center" valign="bottom">6.5
</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;.001
</td>
</tr>
</tbody>
</table>
<a name="t22"></a><table width="100%">
<caption><span>
Table 22: Mean SEP Question 3 Changes in the CIALIS 5Â mg for Once Daily Use Study in Patients with ED and BPH
</span></caption>
<col align="left" width="39.175%">
<col align="left" width="17.500%">
<col align="left" width="22.500%">
<col align="left" width="20.825%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">
Placebo
</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">
CIALIS 5 mg
</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
(N=187)
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
(N=199)
</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">
p-value
</span></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">
Maintenance of Erection (SEP3)
</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Â  Â  Â Baseline
</td>
<td class="Botrule Rrule" align="center" valign="top">
36%
</td>
<td class="Botrule Rrule" align="center" valign="top">
43%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Â  Â  Â Endpoint
</td>
<td class="Botrule Rrule" align="center" valign="top">
48%
</td>
<td class="Botrule Rrule" align="center" valign="top">
72%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
Â  Â  Â Change from Baseline to Week 12
</td>
<td class="Botrule Rrule" align="center" valign="top">
12%
</td>
<td class="Botrule Rrule" align="center" valign="top">
32%
</td>
<td class="Botrule Rrule" align="center" valign="top">
&lt;.001
</td>
</tr>
</tbody>
</table>
<p>CIALIS for once daily use resulted in improvement in the IPSS total score at the first scheduled observation (week 2) and throughout the 12 weeks of treatment (<span class="Italics">see </span><a href="#f08">Figure 8</a>).
</p>
<div class="Figure">
<a name="f08"></a><img alt="Figure 8
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=cialis-uspi-f008-v1.jpg"><p class="MultiMediaCaption">Figure 8: Mean IPSS Changes in ED/BPH Patients by Visit in Study L
</p>
</div>
<p>In this study, the effect of CIALIS 5Â mg once daily on Q<span class="Sub">max</span> was evaluated as a safety endpoint. Mean Q<span class="Sub">max</span> increased from baseline in both the treatment and placebo groups (CIALIS 5Â mg: 1.6Â mL/sec, placebo: 1.2Â mL/sec); however, these changes were not significantly different between groups.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s123"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_Aphena"></a><a name="section-14.1"></a><p></p>
<table border="0" cellpadding="1" cellspacing="1">
<colgroup><col width="100%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" valign="bottom"><p class="First">Repackaged by Aphena Pharma Solutions - TN.<br>See <span class="Bold Italics"><a href="#Repack">Repackaging Information</a></span> for available configurations.</p></td></tr>
<tr class="Last"><td align="left" valign="bottom"><img alt="Aphena Pharma Solutions - TN" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=Aphena.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s124"></a><a name="section-14.2"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">CIALIS (tadalafil) is supplied as follows:
</p>
<p>Four strengths of almond-shaped tablets are available in different sizes and different shades of yellow, and supplied in the following package sizes:
</p>
<table width="100%">
<col align="left" width="24.300%">
<col align="left" width="75.700%">
<tbody class="Headless">
<tr class="First"><td align="left" colspan="2" valign="top">
2.5Â mg tablets debossed with â€œC 2 1/2â€?
</td></tr>
<tr>
<td align="left" valign="middle">
Â  Â  Â <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> of 2 x 15
</td>
<td align="left" valign="middle">
NDC 0002-4465-34
</td>
</tr>
<tr><td align="left" colspan="2" valign="top">
5Â mg tablets debossed with â€œC 5â€?
</td></tr>
<tr>
<td align="left" valign="middle">
Â  Â  Â Bottles of 30
</td>
<td align="left" valign="middle">
NDC 0002-4462-30
</td>
</tr>
<tr>
<td align="left" valign="middle">
Â  Â  Â <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span> of 2 x 15
</td>
<td align="left" valign="middle">
NDC 0002-4462-34
</td>
</tr>
<tr><td align="left" colspan="2" valign="top">
10Â mg tablets debossed with â€œC 10â€?
</td></tr>
<tr>
<td align="left" valign="middle">
Â  Â  Â Bottles of 30
</td>
<td align="left" valign="middle">
NDC 0002-4463-30
</td>
</tr>
<tr><td align="left" colspan="2" valign="top">
20Â mg tablets debossed with â€œC 20â€?
</td></tr>
<tr class="Last">
<td align="left" valign="middle">
Â  Â  Â Bottles of 30
</td>
<td align="left" valign="middle">
NDC 0002-4464-30
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="s125"></a><a name="section-14.3"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [seeÂ USP Controlled Room Temperature].</p>
<p>Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s126"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">â€œSee FDA-approved patient labeling (<a href="#sppi">Patient Information</a>)â€?
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s127"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Nitrates</h2>
<p class="First">Physicians should discuss with patients the contraindication of CIALIS with regular and/or intermittent use of organic nitrates. Patients should be counseled that concomitant use of CIALIS with nitrates could cause blood pressure to suddenly drop to an unsafe level, resulting in <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or even <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>Physicians should discuss with patients the appropriate action in the event that they experience anginal <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> requiring nitroglycerin following intake of CIALIS. In such a patient, who has taken CIALIS, where nitrate administration is deemed medically necessary for a life-threatening situation, at least 48 hours should have elapsed after the last dose of CIALIS before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring. Therefore, patients who experience anginal <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> after taking CIALIS should seek immediate medical attention <span class="Italics">[see Contraindications (<a href="#s25">4.1</a>) and Warnings and Precautions (<a href="#s27">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s128"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Cardiovascular Considerations</h2>
<p class="First">Physicians should consider the potential cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Physicians should advise patients who experience symptoms upon initiation of sexual activity to refrain from further sexual activity and seek immediate medical attention <span class="Italics">[see Warnings and Precautions (<a href="#s27">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s129"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Concomitant Use with Drugs Which Lower Blood Pressure</h2>
<p class="First">Physicians should discuss with patients the potential for CIALIS to augment the blood-pressure-lowering effect of alpha-blockers and antihypertensive medications <span class="Italics">[see Warnings and Precautions (<a href="#s32">5.6</a>), Drug Interactions (<a href="#s50">7.1</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s130"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Potential for Drug Interactions When Taking CIALIS for Once Daily Use</h2>
<p class="First">Physicians should discuss with patients the clinical implications of continuous exposure to tadalafil when prescribing CIALIS for once daily use, especially the potential for interactions with medications (e.g., nitrates, alpha-blockers, antihypertensives and potent inhibitors of cytochrome P450 3A4) and with substantial consumption of alcohol. <span class="Italics">[see Dosage and Administration (<a href="#s17">2.7</a>), Warnings and Precautions (<a href="#s32">5.6</a>), Drug Interactions (<a href="#s50">7.1</a>, <a href="#s55">7.2</a>), Clinical Pharmacology (<a href="#s83">12.2</a>), and Clinical Studies (<a href="#s120">14.2</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s131"></a><a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></h2>
<p class="First">There have been rare reports of prolonged erections greater than 4 hours and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (<span class="product-label-link" type="condition" conceptid="4213599" conceptname="Painful penile erection">painful erections</span> greater than 6 hours in duration) for this class of compounds. <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span>, if not treated promptly, can result in irreversible damage to the erectile tissue. Physicians should advise patients who have an erection lasting greater than 4 hours, whether painful or not, to seek emergency medical attention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s132"></a><a name="section-15.6"></a><p></p>
<h2>17.6 Vision</h2>
<p class="First">Physicians should advise patients to stop use of all PDE5 inhibitors, including CIALIS, and seek medical attention in the event of a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in one or both eyes. Such an event may be a sign of non-arteritic anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span> (NAION), a cause of decreased vision, including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or other factors. Physicians should also discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators such as PDE5 inhibitors <span class="Italics">[see Warnings and Precautions (<a href="#s30">5.4</a>) and Adverse Reactions (<a href="#s48">6.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s133"></a><a name="section-15.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="374053" conceptname="Sudden hearing loss">Sudden Hearing Loss</span></h2>
<p class="First">Physicians should advise patients to stop taking PDE5 inhibitors, including CIALIS, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, have been reported in temporal association to the intake of PDE5 inhibitors, including CIALIS. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors <span class="Italics">[see Adverse Reactions (<a href="#s45">6.1</a>, <a href="#s48">6.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s134"></a><a name="section-15.8"></a><p></p>
<h2>17.8 Alcohol</h2>
<p class="First">Patients should be made aware that both alcohol and CIALIS, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Therefore, physicians should inform patients that substantial consumption of alcohol (e.g., 5Â units or greater) in combination with CIALIS can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="Italics">[see Warnings and Precautions (<a href="#s39">5.9</a>), Drug Interactions (<a href="#s50">7.1</a>), and Clinical Pharmacology (<a href="#s83">12.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s135"></a><a name="section-15.9"></a><p></p>
<h2>17.9 <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Disease</span></h2>
<p class="First">The use of CIALIS offers no protection against <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>. Counseling of patients about the protective measures necessary to guard against <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>, including Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV) should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s136"></a><a name="section-15.10"></a><p></p>
<h2>17.10 Recommended Administration
</h2>
<p class="First">Physicians should instruct patients on the appropriate administration of CIALIS to allow optimal use.
</p>
<p>For CIALIS for use as needed in men with ED, patients should be instructed to take one tablet at least 30 minutes before anticipated sexual activity. In most patients, the ability to have sexual intercourse is improved for up to 36 hours.
</p>
<p>For CIALIS for once daily use in men with ED or ED/BPH, patients should be instructed to take one tablet at approximately the same time every day without regard for the timing of sexual activity. Cialis is effective at improving erectile function over the course of therapy.
</p>
<p>For CIALIS for once daily use in men with BPH, patients should be instructed to take one tablet at approximately the same time every day.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="x999"></a><a name="section-16"></a><p></p>
<p class="First">Revision Date 10/2013
</p>
<p><span class="Bold">Marketed by: Lilly USA, LLC<br>Indianapolis, IN 46285, USA</span></p>
<p><span class="Bold">www.cialis.com</span></p>
<p>Copyright Â© 2003, 2013, Eli Lilly and Company. All rights reserved.
</p>
<p>PV 6605 AMP
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="sppi"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">CIALIS<span class="Sup">Â®</span></span><span class="Bold"> (See-AL-iss)</span></p>
<p><span class="Bold">(tadalafil) tablets</span></p>
<p>Read this important information before you start taking CIALIS and each time you get a refill. There may be new information. You may also find it helpful to share this information with your partner. This information does not take the place of talking with your healthcare provider. You and your healthcare provider should talk about CIALIS when you start taking it and at regular checkups. If you do not understand the information, or have questions, talk with your healthcare provider or pharmacist.
</p>
<p><a name="p04"></a><span class="Bold">What Is The Most Important Information I Should Know About CIALIS?</span></p>
<p><span class="Bold">CIALIS can cause your blood pressure to drop suddenly to an unsafe level if it is taken with certain other medicines.</span> You could get dizzy, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, or have a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.
</p>
<p>Do not take CIALIS if you <span class="Bold">take any medicines called â€œnitrates.â€?</span> Nitrates are commonly used to treat angina. Angina is a symptom of heart disease and can cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your chest, jaw, or down your arm.
</p>
<ul class="Disc">
<li>Medicines called nitrates include nitroglycerin that is found in tablets, sprays, ointments, pastes, or patches. Nitrates can also be found in other medicines such as isosorbide dinitrate or isosorbide mononitrate. Some recreational drugs called â€œpoppersâ€? also contain nitrates, such as amyl nitrite and butyl nitrite.
</li>
<li>Ask your healthcare provider or pharmacist if you are not sure if any of your medicines are nitrates.<br>(See <span class="Bold">â€œ<a href="#p01">Who Should Not Take CIALIS?</a>â€?</span>)
</li>
</ul>
<p>Tell all of your healthcare providers that you take CIALIS. If you need emergency medical care for a heart problem, it will be important for your healthcare provider to know when you last took CIALIS.
</p>
<p><span class="Bold">After taking a single tablet, some of the active ingredient of CIALIS remains in your body for more than 2 days.</span> The active ingredient can remain longer if you have problems with your kidneys or liver, or you are taking certain other medications (see <span class="Bold">â€œ<a href="#p02">Can Other Medicines Affect CIALIS?</a>â€?</span>).
</p>
<p>Stop sexual activity and get medical help right away if you get symptoms such as <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> during sex. Sexual activity can put an extra <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> on your heart, especially if your heart is already weak from a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or heart disease.
</p>
<p>See also <span class="Bold">â€œ<a href="#p03">What Are The Possible Side Effects Of CIALIS?</a>â€?</span></p>
<p><span class="Bold">What Is CIALIS?</span></p>
<p>CIALIS is a prescription medicine taken by mouth for the treatment of:
</p>
<ul class="Disc">
<li>men with <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (ED)
</li>
<li>men with symptoms of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH)
</li>
<li>men with both ED and BPH
</li>
</ul>
<p><span class="Bold">CIALIS for the Treatment of ED</span></p>
<p>ED is a condition where the penis does not fill with enough blood to harden and expand when a man is sexually excited, or when he cannot keep an erection. A man who has trouble getting or keeping an erection should see his healthcare provider for help if the condition bothers him. CIALIS helps increase blood flow to the penis and may help men with ED get and keep an erection satisfactory for sexual activity. Once a man has completed sexual activity, blood flow to his penis decreases, and his erection goes away.
</p>
<p>Some form of sexual stimulation is needed for an erection to happen with CIALIS.
</p>
<p>CIALIS does not:
</p>
<ul class="Disc">
<li>cure ED
</li>
<li>increase a man's sexual desire
</li>
<li>protect a man or his partner from <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>, includingÂ HIV. Speak to your healthcare provider about ways to guard against <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.
</li>
<li>serve as a male form of birth control
</li>
</ul>
<p>CIALIS is only for men over the age of 18, including men with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or who have undergone prostatectomy.
</p>
<p><span class="Bold">CIALIS for the Treatment of Symptoms of BPH</span></p>
<p>BPH is a condition that happens in men, where the prostate gland enlarges which can cause urinary symptoms.
</p>
<p><span class="Bold">CIALIS for the Treatment of ED and Symptoms of BPH</span></p>
<p>ED and symptoms of BPH may happen in the same person and at the same time. Men who have both ED and symptoms of BPH may take CIALIS for the treatment of both conditions.
</p>
<p>CIALIS is not for women or children.
</p>
<p><span class="Bold">CIALIS must be used only under a healthcare provider's care.</span></p>
<p><a name="p01"></a><span class="Bold">Who Should Not Take CIALIS?</span></p>
<p><span class="Bold">Do not take CIALIS if you:</span></p>
<ul class="Disc">
<li><span class="Bold">take any medicines called â€œnitratesâ€?.</span></li>
<li>use recreational drugs called â€œpoppersâ€? like amyl nitrite and butyl nitrite. (See <span class="Bold">â€œ<a href="#p04">What Is The Most Important Information I Should Know About CIALIS?</a>â€?</span>)
</li>
<li>
<span class="Bold"></span><span class="Bold">are allergic to CIALIS or ADCIRCA<span class="Sup">Â®</span></span><span class="Bold">, or any of its ingredients.</span> See the end of this leaflet for a complete list of ingredients in CIALIS. Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include:<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips, tongue, or throat
</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> or swallowing
</li>
</ul>
</li>
</ul>
<p>Call your healthcare provider or get help right away if you have any of the symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> listed above.
</p>
<p><span class="Bold">What Should I Tell My Healthcare Provider Before Taking CIALIS?</span></p>
<p>CIALIS is not right for everyone. <span class="Bold">Only your healthcare provider and you can decide if CIALIS is right for you.</span> Before taking CIALIS, tell your healthcare provider about all your medical problems, including if you:
</p>
<ul class="Disc">
<li>
<span class="Bold"></span><span class="Bold">have heart problems</span> such as angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, irregular heartbeats, or have had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Ask your healthcare provider if it is safe for you to have sexual activity. You should not take CIALIS if your healthcare provider has told you not to have sexual activity because of your health problems.
</li>
<li>
<span class="Bold">have <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span> or</span> have high blood pressure that is not controlled
</li>
<li><span class="Bold">have had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></span></li>
<li><span class="Bold">have liver problems</span></li>
<li><span class="Bold">have kidney problems or require dialysis</span></li>
<li>
<span class="Bold">have <span class="product-label-link" type="condition" conceptid="4103381" conceptname="Retinitis pigmentosa">retinitis pigmentosa</span>,</span> a rare geneticÂ (runs in families) eye disease
</li>
<li><span class="Bold">have ever had severe <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>, including a condition called NAION</span></li>
<li><span class="Bold">have <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span></span></li>
<li><span class="Bold">have a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problem</span></li>
<li>
<span class="Bold">have a deformed penis shape</span> or Peyronie's disease
							</li>
<li><span class="Bold">have had an erection that lasted more than 4Â hours</span></li>
<li>
<span class="Bold">have blood cell problems</span> such as <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>
</li>
</ul>
<p><a name="p02"></a><span class="Bold">Can Other Medicines Affect CIALIS?</span></p>
<p>Tell your healthcare provider about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements. CIALIS and other medicines may affect each other. Always check with your healthcare provider before starting or stopping any medicines. Especially tell your healthcare provider if you take any of the following*:
</p>
<ul class="Disc">
<li>medicines called nitrates (see <span class="Bold">â€œ<a href="#p04">What Is The Most Important Information I Should Know About CIALIS?</a>â€?</span>)
</li>
<li>medicines called alpha blockers. These include Hytrin<span class="Sup">Â®</span>Â (terazosin HCl), Flomax<span class="Sup">Â®</span>Â (tamsulosin HCl), Cardura<span class="Sup">Â®</span>Â (doxazosin mesylate), Minipress<span class="Sup">Â®</span>Â (prazosin HCl), Uroxatral<span class="Sup">Â®</span>Â (alfuzosin HCl), Jalyn<span class="Sup">Â®</span> (dutasteride and tamsulosin HCl) or Rapaflo<span class="Sup">Â®</span> (silodosin). Alpha-blockers are sometimes prescribed for prostate problems or high blood pressure. If CIALIS is taken with certain alpha blockers, your blood pressure could suddenly drop. You could get dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>.
</li>
<li>other medicines to treat high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)
</li>
<li>medicines called HIV protease inhibitors, such as ritonavirÂ (Norvir<span class="Sup">Â®</span>, Kaletra<span class="Sup">Â®</span>)
</li>
<li>some types of oral antifungals such as ketoconazole (Nizoral<span class="Sup">Â®</span>), itraconazole (Sporanox<span class="Sup">Â®</span>)
</li>
<li>some types of antibiotics such as clarithromycin (Biaxin<span class="Sup">Â®</span>), telithromycin (Ketek<span class="Sup">Â®</span>), erythromycin (several brand names exist. Please consult your healthcare provider to determine if you are taking this medicine).
</li>
<li>other medicines or treatments for ED.
</li>
<li>CIALIS is also marketed as ADCIRCA for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>. Do not take both CIALIS and ADCIRCA. Do not take sildenafil citrate (Revatio<span class="Sup">Â®</span>) with CIALIS.
</li>
</ul>
<p><span class="Bold">How Should I Take CIALIS?</span></p>
<ul class="Disc">
<li>Take CIALIS exactly as your healthcare provider prescribes it. Your healthcare provider will prescribe the dose that is right for you.
</li>
<li>Some men can only take a low dose of CIALIS or may have to take it less often, because of medical conditions or medicines they take.
</li>
<li>Do not change your dose or the way you take CIALIS without talking to your healthcare provider. Your healthcare provider may lower or raise your dose, depending on how your body reacts to CIALIS and your health condition.
</li>
<li>CIALIS may be taken with or without meals.
</li>
<li>If you take too much CIALIS, call your healthcare provider or emergency room right away.
</li>
</ul>
<p><span class="Bold">How Should I Take CIALIS for Symptoms of BPH?</span></p>
<p><span class="Bold">For symptoms of BPH, CIALIS is taken once daily.</span></p>
<ul class="Disc">
<li><span class="Bold">Do not take CIALIS more than one time each day.</span></li>
<li>Take one CIALIS tablet every day at about the same time of day.
</li>
<li>If you miss a dose, you may take it when you remember but do not take more than one dose per day.
</li>
</ul>
<p><span class="Bold">How Should I Take CIALIS for ED?</span></p>
<p><span class="Bold">For ED, there are two ways to take CIALIS - either for use as needed OR for use once daily.</span></p>
<p><span class="Bold">CIALIS for use as needed:</span></p>
<ul class="Disc">
<li>
<span class="Bold"></span><span class="Bold">Do not take CIALIS more than one time each day.</span>
</li>
<li>Take oneÂ CIALIS tablet before you expect to have sexual activity. You may be able to have sexual activity at 30 minutes after taking CIALIS and up to 36 hours after taking it. You and your healthcare provider should consider this in deciding when you should take CIALIS before sexual activity. Some form of sexual stimulation is needed for an erection to happen with CIALIS.
</li>
<li>Your healthcare provider may change your dose of CIALIS depending on how you respond to the medicine, and on your health condition.
</li>
</ul>
<p><span class="Bold">OR</span></p>
<p><span class="Bold">CIALIS for once daily use is a lower dose you take every day.</span></p>
<ul class="Disc">
<li>
<span class="Bold"></span><span class="Bold">Do not take CIALIS more than one time each day.</span>
</li>
<li>Take one CIALIS tablet every day at about the same time of day. You may attempt sexual activity at any time between doses.
</li>
<li>If you miss a dose, you may take it when you remember but do not take more than one dose per day.</li>
<li>Some form of sexual stimulation is needed for an erection to happen with CIALIS.
</li>
<li>Your healthcare provider may change your dose of CIALIS depending on how you respond to the medicine, and on your health condition.
</li>
</ul>
<p><span class="Bold">How Should I Take CIALIS for Both ED and the Symptoms of BPH?</span></p>
<p><span class="Bold">For both ED and the symptoms of BPH, CIALIS is taken once daily.</span></p>
<ul class="Disc">
<li><span class="Bold">Do not take CIALIS more than one time each day.</span></li>
<li>Take one CIALIS tablet every day at about the same time of day. You may attempt sexual activity at any time between doses.
</li>
<li>If you miss a dose, you may take it when you remember but do not take more than one dose per day.
</li>
<li>Some form of sexual stimulation is needed for an erection to happen with CIALIS.
</li>
</ul>
<p><span class="Bold">What Should I Avoid While Taking CIALIS?</span></p>
<ul class="Disc">
<li>Do not use other ED medicines or ED treatments while taking CIALIS.
</li>
<li>Do not drink too much alcohol when taking CIALISÂ (for example, 5Â glasses of wine or 5 shots of whiskey). Drinking too much alcohol can increase your chances of getting a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or getting dizzy, increasing your heart rate, or lowering your blood pressure.
</li>
</ul>
<p><a name="p03"></a><span class="Bold">What Are The Possible Side Effects Of CIALIS?</span></p>
<p>See <span class="Bold">â€œ<a href="#p04">What Is The Most Important Information I Should Know About CIALIS?</a>â€?</span></p>
<p><span class="Bold">The most common side effects with CIALIS are:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and stuffy or <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>. These side effects usually go away after a few hours. Men who get <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> usually get it 12Â to 24Â hours after taking CIALIS. <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span> usually go away within 2 days.
</p>
<p>Call your healthcare provider if you get any side effect that bothers you or oneÂ that does not go away.
</p>
<p><span class="Bold">Uncommon side effects include:</span></p>
<p>An erection that won't go away (<span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>). If you get an erection that lasts more than 4Â hours, get medical help right away. <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> must be treated as soon as possible or lasting damage can happen to your penis, including the inability to have erections.
</p>
<p>Color vision changes, such as seeing a blue tinge (shade) to objects or having difficulty telling the difference between the colors blue and green.
</p>
<p>In rare instances, men taking PDE5Â inhibitors (oral <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> medicines, including CIALIS) reported a sudden decrease or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in oneÂ or bothÂ eyes. It is not possible to determine whether these events are related directly to these medicines, to other factors such as high blood pressure or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or to a combination of these. If you experience sudden decrease or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, stop taking PDE5 inhibitors, including CIALIS, and call a healthcare provider right away.
</p>
<p>Sudden loss or decrease in hearing, sometimes with ringing in the ears and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, has been rarely reported in people taking PDE5 inhibitors, including CIALIS. It is not possible to determine whether these events are related directly to the PDE5 inhibitors, to other diseases or medications, to other factors, or to a combination of factors. If you experience these symptoms, stop taking CIALIS and contact a healthcare provider right away.
</p>
<p>These are not all the possible side effects of CIALIS. For more information, ask your healthcare provider or pharmacist.
</p>
<p><span class="Bold">How Should I Store CIALIS?</span></p>
<p>Store CIALIS at room temperature between 59Â°Â andÂ 86Â°FÂ (15Â°Â andÂ 30Â°C).
</p>
<p><span class="Bold">Keep CIALIS and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information About CIALIS:</span></p>
<p>Medicines are sometimes prescribed for conditions other than those described in patient information leaflets. Do not use CIALIS for a condition for which it was not prescribed. Do not give CIALIS to other people, even if they have the same symptoms that you have. It may harm them.
</p>
<p>This is a summary of the most important information about CIALIS. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about CIALIS that is written for health providers. For more information you can also visit <span class="Underline">www.cialis.com</span>, or call 1-877-CIALIS1Â (1-877-242-5471).
</p>
<p><span class="Bold">What Are The Ingredients In CIALIS?</span></p>
<p>Active Ingredient: tadalafil
</p>
<p>Inactive Ingredients: croscarmellose sodium, hydroxypropyl cellulose, hypromellose, iron oxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate, talc, titanium dioxide, and triacetin.
</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration
</p>
<p>Rx only
</p>
<p>CIALIS<span class="Sup">Â®</span> (tadalafil) is a registered trademark of Eli Lilly and Company.
</p>
<p>*The brands listed are trademarks of their respective owners and are not trademarks of Eli Lilly and Company. The makers of these brands are not affiliated with and do not endorse Eli Lilly and Company or its products.
</p>
<p>Revision Date October 2011
</p>
<p><span class="Bold">Marketed by: Lilly USA, LLC<br>Indianapolis, IN 46285, USA</span></p>
<p><span class="Underline">www.cialis.com</span></p>
<p>Copyright Â© 2003, 2011, Eli Lilly and Company. All rights reserved.</p>
<p>PV 5227 AMP
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Repack"></a><a name="section-18"></a><p></p>
<h1>Repackaging Information</h1>
<p class="First">Please reference the <span class="Bold Italics"><a href="#s123">How Supplied</a></span> section listed above for a description of individual tablets or capsules.  This drug product has been received by Aphena Pharma - TN in a manufacturer or distributor packaged configuration and repackaged in full compliance with all applicable cGMP regulations.  The package configurations available from Aphena are listed below:</p>
<table border="0" cellpadding="1" cellspacing="1" width="28%">
<colgroup>
<col width="10%">
<col width="18%">
</colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Bold" align="center" valign="bottom">Count</td>
<td align="center" valign="bottom"><span class="Bold">20mg</span></td>
</tr>
<tr>
<td align="center" valign="bottom">2</td>
<td align="center">43353-857-02</td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">4</td>
<td align="center">43353-857-04</td>
</tr>
</tbody>
</table>
<p>Store between 20Â°-25Â°C (68Â°-77Â°F). See USP Controlled Room Temperature.  Dispense in a tight light-resistant container as defined by USP.  Keep this and all drugs out of the reach of children.</p>
<p>Repackaged by:<br><img alt="Aphena Pharma Solutions - TN" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=Aphena.jpg"><br>Cookeville, TN 38506<br><br>20140321AW</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_30b215dd-8ea3-4af9-afb6-2866931f6475"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20mg</h1>
<p class="First">NDC 43353-857 - <span class="Bold">Tadalafil (Cialis<span class="Sup">Â®</span>) 20mg mg</span> - Rx Only<br><img alt="Bottle Label 20mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1da40b7c-c96a-45d2-a3f2-fafad429afd6&amp;name=43353-857.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CIALISÂ 		
					</strong><br><span class="contentTableReg">tadalafil tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43353-857(NDC:0002-4464)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Tadalafil</strong> (Tadalafil) </td>
<td class="formItem">Tadalafil</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydroxypropyl cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromelloses</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium lauryl sulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Triacetin</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (almond) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">C;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43353-857-02</td>
<td class="formItem">2  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:43353-857-04</td>
<td class="formItem">4  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021368</td>
<td class="formItem">11/26/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Aphena Pharma Solutions - Tennessee, LLC
							(128385585)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aphena Pharma Solutions - Tennessee, LLC</td>
<td class="formItem"></td>
<td class="formItem">128385585</td>
<td class="formItem">Repack(43353-857)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6cb64ba8-98f2-4abf-b58f-e721f756eca6</div>
<div>Set id: 1da40b7c-c96a-45d2-a3f2-fafad429afd6</div>
<div>Version: 1</div>
<div>Effective Time: 20140318</div>
</div>
</div>Â <div class="DistributorName">Aphena Pharma Solutions - Tennessee, LLC</div></p>
</body></html>
